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8Abstract
Despite widespread thromboprophylaxis, venous thromboembolic event (VTE) remains  
one of the leading causes of maternal deaths in the Western world. In Finland, VTE is the 
number one cause of maternal deaths. The highest VTE risk occurs during the postpartum 
period. Since the 1980s-1990s, low-molecular-weight heparin (LMWH) has replaced 
unfractionated heparin (UFH) for the management of acute VTE and for VTE prophylaxis 
during pregnancy due its reduced risk of bleeding, more predictable anticoagulant 
response, and longer half-life.
The aim of the study was to evaluate the maternal and neonatal safety and the efficacy of 
the use of LMWH during pregnancy. Moreover, we studied the incidence, risk factors, and 
mortality of postpartum VTE in Finland through 180 days after delivery.
We conducted retrospective observational studies (I-III) at the Department of Obstetrics 
and Gynecology, University Hospital of Helsinki to evaluate the safety and efficacy of 
LMWH during pregnancy. Women with singleton pregnancies treated with LMWH at any 
stage of pregnancy (n=475) in 1994-2007, were included in Study I to evaluate maternal 
and neonatal safety and the efficacy of long-term use of LMWH during pregnancy. Study II
was a sub-study of Study I concerning recurrent VTEs limited to those with a history of 
previous VTE (n=271). In Study III, which was carried out during 2008-2012, we evaluated
whether there is a subsequent decrease in bone mineral density (BMD) after long-term use
of LMWH during pregnancy. Women with (n=92) and without LMWH exposure (n=60) 
during pregnancy were recruited for measurement of BMD by dual-energy X-ray 
absorptiometry (DEXA). Additionally a population-based, controlled cohort study was 
conducted using the combined data of five large registers in Finland (Study IV). In this 
study we evaluated the incidence and risk factors for postpartum VTE in 2001-2011. The 
study population consists of all women with deliveries (N=634292) and a total fertile-aged 
women population without deliveries or medical abortions (N=1232841) in the last 
calendar year. Those women with an inpatient or outpatient admission because of VTE 
after the date of delivery (n=1169) were collected from the Care Register for Health Care 
(HILMO). 
9The incidences of thrombocytopenia, bleeding during pregnancy and delivery, preterm 
delivery, stillbirth, pre-eclampsia, or fetal growth restriction did not differ between 
LMWH-exposed women and healthy controls. The incidence of allergic skin reactions for 
LMWH was low. No HIT or osteoporotic fractures were observed. The incidence of VTE 
despite ongoing LMWH prophylaxis was high, 2.5%. The risk for recurrent VTE despite 
ongoing LMWH was high in women with a history of two or more previous VTEs, prior 
VTE related to hormonal risk factors, prior VTE in connection with antiphospholipid 
antibody syndrome (APS), and use of long-term anticoagulation before pregnancy. The 
risk for recurrent VTE before the intended initiation of LMWH was associated with a 
history of two or more prior VTEs and a history of VTE related to earlier pregnancy. No 
association between decreased BMD and LMWH exposure, when adjusted for potential 
confounding factors, was found. The risk of postpartum VTE was highest during the first 
week after delivery: 37-fold compared with non-pregnant women, declining rapidly 
thereafter to 2-fold through 175 postpartum days. The risk remained elevated for 180 days 
in women with thrombophilia, Cesarean section, multiple birth, varicose veins, and cardiac
disease. Three VTE-related deaths occurred.
In conclusion, we showed that the use of LMWH during pregnancy was safe for both the 
mother and the fetus. The high VTE recurrence rate in our department reflected 
insufficient dosing in high-risk women due to lack of consistent recommendations 
concerning LMWH prophylaxis in high-risk groups. Individual risk assessment and studies
on the optimal dosing of LMWH to prevent recurrent VTE during pregnancy in high-risk 
groups are needed. Because the VTE risk remained elevated for six months after delivery, it
is possible that in the high-risk groups LMWH prophylaxis for six weeks might be too 
short, necessitating more studies to investigate the optimal duration of LMWH 
prophylaxis.   
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Introduction 
The term venous thromboembolic event (VTE) encompasses both deep venous thrombosis 
(DVT) and pulmonary embolism (PE). Despite widespread thromboprophylaxis, VTE 
remains a leading cause of maternal deaths in the Western world, causing 9.3% of all 
maternal deaths in the United States (1). The risk of VTE is 5- to 10-fold higher in pregnant
women than in non-pregnant fertile women  (2-5). The postpartum period is the time of 
the highest risk, 15- to 35-fold that of age-matched non-pregnant non-puerperal women 
(2,3,6,7). 
Because of hazardous adverse effects of earlier used unfractionated heparin (UFH), low-
molecular-weight heparin (LMWH) is today recommended in prevention and treatment of 
acute VTE during pregnancy and prevention of recurrent pregnancy loss in women with 
antiphospholipid antibodies (aPL) (8-10). The knowledge about the safety and efficacy of 
LMWH increases continuously along with the use of LMWH in gestational settings. 
Previous studies of comparatively large sample sizes have demonstrated the safety and 
efficacy of LMWH during pregnancy (11-14). 
The experience of LMWH use in rare cases of women with a high risk of VTE (e.g. prior 
VTE related to high-risk thrombophilias) is, however, increasing slowly. While 
recommendations for pregnancy-related LMWH therapy in common situations are rather 
similar worldwide, the recommendations concerning high-risk cases are mainly based on 
earlier case reports, case series, or studies conducted in non-pregnant patients (10,15). 
Moreover, only a few reports on recurrent VTEs during pregnancy exist (16-18). Because of
limited cohort sizes in high-risk groups, the optimal dose and duration of LMWH 
prophylaxis to prevent recurrent VTE during pregnancy in these patients are unknown 
(10,19). 
Bone loss is a well-recognized hazardous adverse effect of UFH, with observed 
symptomatic osteoporotic fractures in 2-9% of women after long-term use of UFH during 
pregnancy (20,21).  Several case series and animal studies have suggested that the decrease
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in bone mineral density (BMD) with LMWH is less than that seen with UFH  (22-24). It is 
recognized that a decrease in BMD occurs in normal pregnancy and is escalated by 
lactation; this decrease has been, however, demonstrated to be reversible (25,26). Duration
of lactation can vary considerably and a longer time between delivery and BMD 
measurement may disclose this reversible confounding factor.  It is not yet known whether 
long-term LMWH use during pregnancy can lead to a long-term decrease in BMD, i.e. 
several years after delivery. 
Because re-admissions due to postpartum VTE occur at internal medicine departments in 
Finland, the burden of this entity is not visible to obstetricians, and this might lead to an 
underestimation of the actual VTE incidence and a false sense of security. Only a few 
previously published studies with a long (>3 months) follow-up time after delivery exist 
(27,28). One previous study on efficacy of LMWH prophylaxis demonstrated that the 
incidence of postpartum recurrent VTE was 7.0%, and 40% of these events occurred after 
the cessation of the 6-week LMWH prophylaxis – all in high-risk women. This finding 
suggests that postpartum prophylaxis for 6 weeks might be too short in high-risk cases 
(17). 
We conducted a large controlled cohort study on the safety and efficacy of long-term 
LMWH use during pregnancy and a population-based register study on the incidence, risk 
factors, and mortality of postpartum VTEs. 
The use of LMWH in gestational settings is increasing constantly because sicker, older, and
heavier women around the world are currently becoming pregnant. Our aims were to 
investigate the following important issues in order to help clinicians to properly identify 
pregnant women at risk of VTE: 1. The safety of long-term use of LMWH during pregnancy
for the mother and the fetus; 2. The incidence and associated risk factors of recurrent 
antepartum VTE in women with prior VTE; 3. The possibility of subsequent decrease in 
BMD after a pregnancy-related long-term use of LMWH; and 4. The incidence and 
mortality of VTE through 180 postpartum days in order to identify associated risk factors 
during three different postpartum periods and to compare the incidence of postpartum 
VTE with that of non-pregnant fertile women.
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Review of the literature
Venous thromboembolism during pregnancy and during the 
postpartum-period 
Pathophysiology of venous thromboembolic event (VTE) during 
pregnancy 
Pregnancy is associated with several physiological and anatomic changes, which increase 
the risk of VTE. Venous stasis caused by progesterone-induced venous distension, pelvic 
venous compression by the enlarging uterus (29,30) and decreased mobility (31) occur 
during pregnancy. During late pregnancy gravid uterus compresses the right common iliac 
artery, which further compresses the left iliac vein at the point where they intersect, 
leading to the propensity for left leg DVT (>80%) (May-Thurner syndrome) (32,33).  
The increasing amount of estrogen as pregnancy progresses alters the levels of coagulation 
factors responsible for hemostasis (34,35). Substantial rises in plasma levels of fibrinogen, 
von Willebrand factor (vWF), factor (F)VII and FVIII (36) and modest rises in FIX and FX 
(34,35,37) lead to increased thrombin production, measured by increased soluble fibrin 
(38). The increased amount of coagulation factors is not balanced by the increased amount
of anticoagulants;  a decrease in the level of protein S and increased activated protein C 
resistance in turn reduce the anticoagulant activity during pregnancy  (34). Maternal 
plasma fibrinolytic activity decreases in pregnancy due to increased plasminogen activator 
inhibitor (plasminogen activator inhibitor -1 and 2) activity and decreased tissue 
plasminogen activator (39). Vascular injury to the pelvic vessels, which can occur after 
normal or instrumental vaginal delivery and especially by Cesarean section (CS), explains 
the pathophysiology of VTE in the postpartum period compounded by postpartum 
immobility (40). Figure 1 depicts the coagulation cascade on the cell membrane of platelet. 
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residual risk persists for 12 weeks after delivery (48). 
Pregnancy-associated VTE manifests usually as deep venous thrombosis (DVT) or 
pulmonary embolism (PE). DVT in the lower limb is the most common type of pregnancy-
associated VTE, accounting for 75-80% of cases, with the remaining 20-25% caused by PE 
(7,46,49). The most common site for DVT has been reported to be in the proximal veins 
(femoral or iliac veins), in 71% of cases, without simultaneously thrombosis in calf vein 
(50,51). Isolated DVT of a calf vein is reported in only 6% of cases (50), whereas the 
majority of non-pregnant patients (58-87%) have proximal thrombosis with involvement 
of the calf veins, suggesting that perhaps the pathophysiology of the VTE during pregnancy
differs from that in the general population.  Even though upper extremity DVT is 
uncommon, it has been increasingly reported during pregnancy, particularly with the use 
of assisted reproductive techniques (ARTs) and with a history of ovarian hyperstimulation 
syndrome (OHSS) (52,53). The incidence of upper extremity DVT is estimated to be 0.08-
0.11% of ART treatment cycles, and the jugular vein appears to be involved more often 
than the subclavian vein (53). Upper extremity VTE associated with ART and OHSS has 
recently been proposed to be induced by drainage of estradiol-containing ascites to the 
jugular and subclavian veins via the thoracic and lymphatic ducts (54). Cerebral vein 
thrombosis (CVT) is rare, occurring in 1.32/100000/year in high-income countries; the 
incidence is higher in middle- and low-income countries (55). Risk for CVT is increased 
during childhood and pregnancy. It may account for a substantial portion of all pregnancy 
strokes (56). CVTs are now being diagnosed with rising frequency due to the increased use 
of magnetic resonance imaging (MRI) for investigating patients with acute and subacute 
headaches and new onset seizures (55). 
As a result of better recognition of women at risk of VTE and widespread 
thromboprophylaxis, VTE is no longer the leading cause of maternal mortality worldwide, 
as it was a few years earlier (57). However, it remains one of the most important causes of 
direct pregnancy-associated deaths in Western countries (57). Eighteen deaths due to VTE 
(16 due to PE and 2 due to CVT) occurred in the UK during 2006-2008, which is notably 
fewer than the 41 deaths in 2003-2005 (57).  In Finland, however, VTE seems to be the 
leading cause of maternal deaths; 17 of 52 maternal deaths (33%) occurred due to VTE or 
amnionic fluid embolism in 1996-2014 (58). Because pregnancy-associated VTE is often 
massive (59), it is an important cause of long-term maternal morbidity in the form of post-
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thrombotic syndrome, comprising swelling, pain, discomfort, eczema, varices and ulcer(s) 
of the affected limb (60). 
Diagnosis of VTE during pregnancy 
The clinical diagnosis of VTE is difficult because symptoms such as leg swelling, muscular 
pain of the lower limbs, and shortness of breath are common during pregnancy and are 
usually not associated with VTE (61). Typical symptoms or signs of VTE are presented in 
table 1.  Measurement of D-dimer (a lytic product of crosslinked fibrin) is currently not 
recommended in the investigation of suspected VTE since D-dimer levels increase as 
pregnancy progresses, peaking on the first postpartum day (62). The first test in pregnant 
women suspected to have DVT is compression ultrasonography (CUS) of the lower 
extremities and/or iliac veins, unless symptoms in the upper extremity exist (63). When 
suspecting a calf vein DVT, CUS is recommended to be repeated in 7 days if negative 
because it is less accurate below the knee, with a sensitivity of 11–100% and a specificity of 
90–100% (64,65). Since approximately 10% of iliac DVTs are missed on CUS, in case of 
high suspicion, CUS should be repeated and, if negative, magnetic resonance imaging 
(MRI) should be considered (66).
When suspecting PE, a chest X-ray can rule out other pathologies, such as pneumonia or 
pneumothorax, which may mimic the symptoms of PE (49). It should be performed first, 
although it is normal in >50% of patients with diagnosed PE (49). Bilateral CUS could also 
be performed when suspecting PE. If this confirms a DVT, there is no need for further 
investigations because therapy is often the same for both conditions and unnecessary 
radiation to the mother and fetus must be avoided (67). However, CUS in this indication is 
not very useful because in a study with 67 pregnant women with suspected PE no cases of 
DVT were found (68). If suspicion of PE remains and chest X-ray and CUS are normal a 
computed tomography pulmonary angiogram (CTPA) or ventilation/perfusion (V/Q) lung 
scan is recommended (67). Both CTPA and V/Q lung scan have equivalent clinical negative
predictive value: 99% for CTPA and 100% for V/Q (69). CTPA is, however, better than V/Q
lung scan if chest X-ray is abnormal since it may also identify alternate diagnoses such as 
aortic dissection (70,71). 
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The adverse effect of lung imaging is the risk of ionizing radiation to the fetus and mother. 
However, the fetal radiation dose caused by chest X-ray at any gestational age is negligible 
(<0.1 mGy) (72). The estimated fetal radiation exposure from CTPA (0.1 mGy) is similar to 
that from V/Q lung scan (0.5 mGy). These exposures are well below the thresholds 
associated with teratogenesis and risk of childhood cancer (73). The radiation dose to the 
breast tissue with CTPA (up to 20 mGy) may be 20- to 100-fold that with V/Q lung scan, 
raising a concern of a risk of breast cancer (74). Breast tissue during pregnancy is very 
sensitive to radiation (73,75), but radiation doses can be halved by using a lower peak 
kilovoltage (120 kVp), automatic tube current modulation, and bismuth anterior chest wall
shields (75). In Finland, CTPA has been the modality of choice nowadays, but the use of 
V/Q lung scan is increasing worldwide when chest X-ray is normal. V/Q lung scan can be 
recommended over CTPA in pregnant women due to concern of breast radiation (personal 
communication with Risto Kaaja). Magnetic resonance pulmonary angiography is being 
investigated in detecting PE in pregnancy (76). 
In cases with suspected CVT, MRI and magnetic resonance venography are more valuable 
Collapse
Shock
Table 1: Symptoms and signs of VTE during pregnancy
Deep vein thrombosis (DVT) Pulmonary embolism (PE)
Painful and warm leg Pleuritic chest pain
Swelling Dyspnea
Erythema Tachypnea
Tenderness Cough
Lower abdominal or back pain Hemoptysis
Tachycardia
Raised jugular venous pressure
Cerebral vein thrombosis (CVT) Focal chest signs
Headache
Vomiting
Photophobia
Seizures Upper extremity DVT
Impaired consciousness Unilateral swelling
Focal neurological signs Pain 
Dilated collateral circulation
Modified table from Book: Cohen H, O’Brien P. Disorders of
Thrombosis and Hemostasis in Pregnancy A Guide to
Management. 2nd.ed. Springer-Verlag London 2015; p. 85.and
Stone et al. 2016
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and sensitive to the diagnosis of CVT than computed tomography (77) 
Risk factors of VTE during pregnancy
Previous VTE 
The risk of VTE is reported to be higher in the third trimester than in the second or first 
trimester, being particular high in puerperium (4). The increased risk of VTE is already 
present from the first trimester often before the anatomic changes of pregnancy occur (78).
In recent years, attention has been given to stratifying risk factors of VTE in order to 
reduce the rate of these events (79). The most important risk factor for VTE in pregnancy is
a personal history of VTE, with the increased recurrence risk being 3- to 4-fold, and 15-
25% of all VTE cases in pregnancy are recurrent events (80). Circumstances of previous 
VTE are essential to stratify because they considerably affect the risk of recurrent event 
(81). A woman with a temporary risk factor associated with prior VTE (trauma, surgery, 
long-haul flight, or intravenous drug use) has a very low risk of antenatal VTE (82). If 
previous VTE is estrogen-provoked (during previous pregnancy or with the use of 
estrogen-containing contraception pill), the recurrence risk is notable higher, 
approximately 10% in subsequent pregnancies (80,83,84). If prior VTE was unprovoked, it 
has been shown to be associated with an increased risk of recurrence relative to those 
provoked by a temporary risk factor in non-pregnant populations (85). A positive family 
history increased the risk of pregnancy-associated VTE also regardless of the risk factors 
precipitating the thrombosis (86). 
Thrombophilia
      
The next strongest risk factor for pregnancy-associated VTE is the presence of a 
thrombophilia, which means alterations of acquired or inherited coagulation factors 
predisposing to thrombosis (87). Risk and prevalence of VTE during pregnancy in relation 
to inherited thrombophilia are presented in table 2.  
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Thrombophilia can increase VTE risk of almost any risk factor, and together with 
pregnancy, it has important harmful effects for both mother and fetus (87). Different 
thrombophilias possess different levels of VTE risk (81).  
Hereditary thrombophilias
The prevalence of inherited thrombophilia is 20-50% in women with VTE events during 
pregnancy or during the postpartum period (81). Inherited thrombophilia can be 
homozygous or heterozygous (88). 
Activated Factor V (FVa) is a cofactor required for thrombin generation. FVa is inactivated 
by Activated Protein C (APC). In Caucasian populations, inherited APC resistance is most 
often caused by FV Leiden gene point mutation (R506Q) (89),  which is the most common 
thrombophilia. The prevalence of heterozygous FV Leiden mutation is dependent on the 
population observed. It has been reported to be 5% in white individuals, the highest figure 
of 7% observed in Southern Europe and the lowest figure of 0-0.6% in Africa (90,91). Its 
prevalence in Finland is estimated to be 2-3% (92). Acquired APC resistance may occur in 
connection with pregnancy or antiphospholipid antibodies (aPLs) (89) 
The prothrombin gene mutation is due to a single G20210A nucleotide change in the 
prothrombin gene, which increases thrombin generation (93,94). The prothrombin gene 
Thrombophilia Pregnancy-associated VTE Prevalence in women  
OR (95% CI) with VTE in pregnancy (%)
Antithrombin deficiency 4.7 (1.3-17.0) 7-12 %
Protein C deficiency 4.8 (2.2-10.6) 10
Protein S deficiency 3.2 (1.5-6.9) 8
Factor V Leiden (homozygous) 34.4 (9.9-120.1) 9-17
Factor V Leiden (heterozygous) 8.3 (5.4-12.7) 8-44
Prothrombin (homozygous) 26.3 (1.2-559.3) ..
Prothrombin (heterozygous) 6.8 (2.5-18.8) 3-10
Data from (Robertson et al. 2006,Lim et al.2007)
Table 2: Risk and prevalence of VTE during pregnancy according to
inherited thrombophilia
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mutation is inherited dominantly in autosomes and is found in 2% of white individuals in 
the general population (95).
Antithrombin inactivates multiple enzymes generated by the coagulation cascade: mainly 
thrombin, FX, IX, XI, XII, and proteins S and C, and hence, regulates generation of 
thrombin and inhibits already generated thrombin (96). AT deficiency is a rare autosomal 
dominant disorder, caused by mutations in the AT gene. AT deficiency is considered one of
the most severe thrombophilias. Over 250 different mutations have been reported thus far 
(97). Type 1 AT deficiency is characterized by a quantitative reduction of antithrombin and 
is a stronger risk factor for VTE than type 2 AT deficiency, which is characterized by the 
production of qualitatively abnormal antithrombin (96). However in Finland, type 2 AT 
deficiency is caused predominantly by a single point mutation Pro73Leu, which is also 
associated with a significant thrombotic risk, up to 100-fold in some families (97). The 
estimated prevalence of AT deficiency has been found to be 5-17 per 10000 individuals 
(98). Thrombosis has been reported to complicate approximately 9% of pregnancies in 
women with AT deficiency who are ≥35 years and 6% in those  <35 years (99), which is 30-
fold (5- to 50-fold) higher than in those without AT deficiency (97). 
APC inactivates FVIIIa and Va, thus inhibiting thrombin generation (100). Protein C 
deficiency is associated with 270 different mutations and  results in impairment of the 
ability to control coagulation through destruction of FVa and FVIIIa. The prevalence of 
mild (heterozygous) protein C deficiency in the general population is estimated at 1 per 
200-500 individuals. Severe protein C deficiency is rare, 14–50 per 10000 individuals, and
is usually associated with severe prothrombotic diseases  (101).  
Protein S is a vitamin K–dependent anticoagulant protein that acts as a cofactor for APC in
the inactivation of coagulation factors Va and VIIIa (102). Sixty percent of protein S binds 
to C4b binding protein, and the remaining 40% is responsible for the anticoagulant 
activity. Inherited protein S deficiency is uncommon (less than 1% of the general 
population) and may be either quantitative (type I, more common, approximately 2/3 of 
cases) or qualitative (types II and III, less common). Protein S values vary with age and 
gender. In addition, acquired PS deficiency is common and known to occur with acute 
VTE, nephrotic syndrome, inflammatory syndromes, disseminated intravascular 
coagulation, liver disease, malnutrition, pregnancy, estrogen therapy, vitamin K deficiency,
and VKAs (103).  
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Factor VIII (FVIII) plays an essential role in normal hemostasis by acting as a critical 
cofactor for activated factor IX. An increasing amount of case-control studies support the 
hypothesis that increased FVIII levels are associated with VTE and recurrent VTEs (104).  
An odds ratio (OR) for VTE of 4.8 (95% CI 2.3-10.0) was determined for individuals with 
high FVIII levels (105). 
Acquired thrombophilias 
Antiphospholipid syndrome (APS) is an acquired thrombophilia with the presence of 
persistently positive antiphospholipid antibodies (aPL): lupus anticoagulant and/or 
anticardiolipin and/or anti-β2-glycoprotein 1 antibodies on two consecutive occasions at 
least 12 weeks apart in association with a history of arterial or venous thrombosis or 
adverse pregnancy outcomes. The risk of arterial or venous thrombosis is estimated to be 
0.5-30% (106).It is widely accepted that lupus anticoagulant is a more important predictor 
for VTE than anticardiolipin and anti-β2-glycoprotein 1 antibodies (107). Triple positivity 
correlates better with thrombosis and pregnancy morbidity than any other aPL profile 
(107). Antiphospholipid antibodies have been reported to activate endothelium and 
complement (108).They also inhibit the anticoagulant properties of APC (109).Up-
regulation of the tissue factor pathway caused by aPLs, impairs fibrinolysis by reducing 
tissue factor pathway inhibitor activity (110).  
It is not known why APS in some patients develops into VTEs, while others present with 
morbidity in pregnancy. While a minority of patients may also develop a life-threatening 
“catastrophic” form of APS with multiple organ involvement and a high death rate, others 
never develop any aPL- related manifestation (111).  
The risk for VTE in pregnant women with APS is highest among those with a history of 
thrombosis and in those with all above mentioned three test positive (87). The risk of 
recurrent thrombosis during pregnancy, despite thromboprophylaxis, was 5% in women 
with APS  (112). 
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Thrombophilias and pregnancy complications 
APLs are also associated with other adverse pregnancy outcomes besides VTE. A diagnosis 
of obstetric APS requires at least one of these criteria together with persistently positive 
tests for one or more aPLs: 1. Three or more consecutive unexplained miscarriages before 
the 10th week of gestation, 2. One or more unexplained deaths of a morphologically 
normal fetus at 10 weeks’ gestation or older , 3. One or more premature births of a 
morphologically normal fetus at 34 weeks’ gestation or younger associated with severe pre-
eclampsia or placental insufficiency (113). Fifteen percent of women with recurrent 
miscarriage have obstetric APS (114,115). In a prospective study, with recruitment prior to 
pregnancy, the miscarriage rate was shown to be 90% with no pharmacological treatment 
(114). 
The mechanism of pregnancy losses has been demonstrated to be the harmful effect of 
aPLs on implantation by affecting the function of both the uterine decidua and the 
trophoplasts (116,117). Additionally, the role of complement activation with focal necrosis, 
apoptosis, and neutrophil infiltration in aPL-related pregnancy loss has been shown (118). 
Annexin V is a protein, which normally serves as an anticoagulant on trophoblast 
membranes in placenta by blocking FXa and protrombin. Thrombosis during the 
development of the normal materno-placental circulation may arise via interference with 
this function. Moreover, women with APS have disrupted and reduced annexin V binding 
to the surface of trophoblastic cells (119). 
Preterm delivery is common in women with obstetric APS. The premature delivery rate 
(before 37 gestational weeks) was 32%, predisposing offspring to the consequences of 
premature delivery such as low birth weight and behavioral abnormalities (120,121). 
Almost 30% of these offspring have been shown to passively acquire aPL, predisposing 
them to the risk of hemorrhagic and thrombotic complications (122). 
Because of the assumption that aPL induces thrombosis causing pregnancy loss, it has 
been assumed that any prothrombotic state may also increase the change of  pregnancy 
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loss by causing placental insufficiency due to placental vascular thrombosis (123). It is, 
however, controversial whether hereditary thrombophilia is associated with obstetric 
complications  (124,125)  Evidence from a meta-analysis suggests that  hereditary 
thrombophilia might be a contributory factor rather than a primary cause of pregnancy 
complications (124).  According to a systematic review, FV Leiden mutation and 
Prothrombin gene mutation had a weak association with late pregnancy complications 
(second trimester pregnancy loss, pre-eclampsia, intrauterine fetal growth restriction 
(FGR), and placental abruption) (88). However, a meta-analysis of prospective cohort 
studies concluded that those with FV Leiden mutation have a small absolute increased risk 
of late pregnancy loss (OR 1.52, 95% CI 1.06-2.19). Women with FV Leiden mutation or 
Prothrombin mutation appeared not to be at increased risk of pre-eclampsia or FGR (126). 
In a population-based study in Finland, Factor V Leiden mutation was not observed to be a
significant risk factor for pre-eclampsia (127); it was, however, associated with stillbirth 
(128). 
           
Other risk factors for pregnancy-associated VTE
 Clinical risk factors for VTE are presented in table 3. Obesity is common in non-pregnant 
as well as pregnant populations in Western countries. Body mass index (BMI) is over 30 
kg/m2 (obesity) in 27% of women and between 25 and 30 kg/m2 (overweight) in 31%. The 
proportion of morbidly obese (BMI over 40 kg/m2) women is 4% (129). Obesity is reported
to be associated with a higher risk of PE (OR 14.9, 95% CI: 3.0-74.8) than of DVT (OR 4.4, 
95% CI: 1.6-11.9) as compared with normal-weight controls (130). The risk of VTE 
increased with age from 1.64/1000 deliveries in those < 35 years to 2.27/1000 deliveries in
those > 35 years (46). 
Maternal smoking during pregnancy has been shown to be a risk factor for VTE during 
pregnancy, but no clear difference in the risk of DVT versus the risk of PE in relation to 
smoking was found (130). 
Cesarean section increases the risk of postpartum VTE 4-fold compared with vaginal 
delivery (131). In a recent meta-analysis with over 50 reports, the pooled OR was 3.7 (95% 
CI 3.0-4.6) compared with vaginal deliveries. The incidence of VTE was 2.6/1000 CS. The 
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higher risk of VTE was associated with an emergency CS compared with an elective CS, 
with incidences of 1.6/1000 pregnancies (95% CI 1.2-2.2) and 2.4/1000 pregnancies (95% 
CI 0.8- 4.5), respectively (131).
Immobilization during pregnancy has been shown to be associated with the risk of VTE, 
especially in conjunction with higher BMI (132). Travel duration in excess of 4 h (not just 
by air) has also been proved to increase the risk of VTE due to immobility during the travel 
Risk factor Adjusted OR/HR (95% CI)
Antepartum risk
62.3 (11.5-337.0)
7.7 (3.2-19.0)
Assisted reproductive techniques - first trimester only 4.6 (2.9-7.2)
Spontaneous twins 2.6 (1.1-6.2)
Antepartum hemorrhage 2.3 (1.8-2.8)
Smoking (10-30 cigarettes/day prior to or during pregnancy) 2.1 (1.3-3.4)
1.8 (1.3-2.4)
Weight gain <7 kg 1.7 (1.1-2.6)
Postpartum
40.1 (8.0-201.5)
10.8 (4.0-28.8)
Postpartum infection following vaginal delivery 20.2 (6.4-63.5)
Postpartum infection following cesarean section 6.2 (2.4-16.2)
Postpartum hemorrhage ≥1 litre with surgery 12.0 (3.9-36.9)
Postpartum hemorrhage ≥1 litre with no surgery 4.1 (2.3-7.3)
Pre-eclampsia with fetal growth restriction 5.8 (2.1-16.0)
Fetal growth restriction (birth weight<2.5 percentile) 3.8 (1.4-10.2)
Smoking (10-30 cigarettes/day prior to or during pregnancy) 3.4 (2.0-4.4)
Smoking (5-9 cigarettes/day prior to or during pregnancy) 2.0 (1.1-3.7)
Pre-eclampsia 3.1 (1.8-5.3)
Hyperemesis 2.5 (2.0-3.2)
Pre-pregnancy BMI<25 kg/m2 - no immobilization 2.4 (1.7-3.3)
Pre-pregnancy BMI≥25 kg/m2 - no immobilization 1.8 (1.3-2.4)
Risk period not specified
Systemic lupus erythematosus 8.7 (5.8-13.0)
Blood transfusion 7.6(6.2-9.4)
Heart disease 7.1 (6.2-8.3)
Sickle cell disease 6.7 (4.4-10.1)
Multiple pregnancy 4.2 (1.8-9.7)
5.3 (2.1-13.5)
Assisted reproductive techniques 1.8 (1.4-2.3)
Anemia 2.6 (2.2-2.9)
Diabetes 2.0 (1.4-2.7)
Hypertension 1.8 (1.4-2.3)
Weight gain >21 kg (vs. 7-21 kg) 1.6 (1.1-2.6)
Parity>1 1.5 (1.1-1.9)
OR, odds ratio; HR, hazard ratio; BMI, body mass index
Table 3: Clinical risk factors for VTE determined from case-control or cross-
sectional studies
Immobility (strict bedrest for≥1 week with BMI≥25 kg/m2)
Immobility (strict bedrest for≥1 week with BMI<25 kg/m2)
Pre-pregnancy BMI≥25 kg/m2 - no immobilization
Immobility (strict bedrest antepartally for≥1 week with BMI≥25 kg/m2)
Immobility (strict bedrest antepartally for≥1 week with BMI<25 kg/m2)
BMI≥30 kg/m2
Data from Lindqvist et al.1999, Simpson et al. 2001, James et al. 2006, Jacobsen et al.  2008,
Knight et al. 2008, Henriksson 2013,  Jacobsen 2008
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(133). 
Assisted reproductive techniques increases the risk of VTE, mainly due to OHSS, both 
antenatally (OR 4.,4, 95% CI 2.6-7.5) and postnatally (OR 2.2, 95% CI 1.1-4.3) (132). 
Surgery during pregnancy is associated with increased risk of VTE (including termination 
of pregnancy and operations performed due to ectopic pregnancy) because of damage from
surgery to vessel walls and platelet aggregation at the site of injury, engaging the clotting 
cascade and releasing clotting factors into the circulatory system (134). Hyperemesis may 
increase the risk of VTE due to dehydration (46). 
Ethnicity affects the risk of VTE. The risk of VTE is observed to be lower in white women 
(1.75/1000 deliveries) than in black women (2.64/1000 deliveries). The rate for black 
women was 64% higher than that for women of other races at all ages. The risk of VTE is 
lowest in Asian women (1.07/1000 deliveries) (46). 
Risk factors for pregnancy-associated VTE are partially different during the antepartum 
and postpartum periods. Multiple pregnancy (often conceived after ART and related to 
OHSS) (7,45,135) and gestational diabetes (135) were significant risk factors for 
antepartum VTE. Strong postpartum risk factors were found to be CS and pre-eclampsia 
(135). Postpartum hemorrhage (often requires re-operation or transfusion) and infection 
were also associated with the risk of postpartum VTE (46).
Recommendations for treatment and prophylaxis of 
pregnancy-associated VTE
Although evidence-based recommendations for the use of anticoagulants during pregnancy
exist, they are based mainly on observational studies and data extrapolated from non-
pregnant patients. There are a few important questions that should be addressed when 
planning optimal care: risks of anticoagulants during pregnancy and breastfeeding, best 
treatment strategy of acute VTE during pregnancy, prevention of pregnancy-associated 
VTE, and peripartum anticoagulation.  The current guidelines are listed in table 4.  
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Because high-quality data in pregnancy are lacking (randomized prospective studies), the 
published recommendations differ (79). An example of such a difference would be in 
preventing VTE in situations with asymptomatic thrombophilias (especially milder); while 
some guidelines recommend clinical surveillance, others suggest considering antepartum 
LMWH. There are also differences in preferred LMWH dosages (prophylactic, 
intermediate, weight-adjusted treatment doses) for preventing recurrent VTE in situations 
with different thrombophilias.   
Since the 1980s-1990s,  LMWH has been widely used for prophylaxis and treatment of 
VTE during pregnancy (8,9,136). It replaced UFH after large trials in non-pregnant 
patients showed that LMWHs are at least as safe and effective as UFH (137,138).  
Nowadays, all guidelines recommend LMWH over UFH because it is considered safer in 
terms of the risks of osteoporosis, HIT, allergy, and bleeding complications (19).  It is also 
easier to use thanks to pre-filled syringes, dosing once or twice a day, and little or no need 
to monitor the effect of anticoagulation (139). 
It must be noted, however, that inconsistency exists between authors in their risk 
thresholds for recommending LMWH prophylaxis, and thus, the prophylaxis thresholds 
were determined by the majority result of an anonymous vote of the authors. The risk 
thresholds chosen by authors ranged from 1% to 5% for antepartum prophylaxis and from 
1% to 3% for postpartum prophylaxis.  The panel ultimately assessed the need for 
thromboprophylaxis by using a risk threshold ≥ 3% for both antepartum and postpartum 
periods. This means that for risk factors for which only case-control data are available, a 
relative risk of at least 30-fold antepartum and 60-fold postpartum are required to reach 
these thresholds (assuming antepartum and postpartum baseline risks of 0.1% and 0.05% 
respectively) (140). 
Table 4. Current guidelines for the treatment and prophylaxis
of obstetrics-associated VTE
ACOG American College of Obstetricians and Gynecologists; www.acog.org
SOGC Society of Obstetricians and Gynaecologists of Canada; www.sogc.org
RCOG Royal College of Obstetricians and Gynaecologists; www.rcog.org.uk
ACCP American College of Chest Physicians; www.chestnet.org
Clinicians from Australia and New Zealand;
www.nationalwomenshealth.adhb.govt.nz
26
Management of acute VTE
Once VTE is confirmed, anticoagulation should be initiated. LMWH is recommended to be 
used twice daily as weight-adjusted treatment doses calculated by early pregnancy weight. 
Table 5 shows the recommended doses for common LMWHs for both initial and 
maintenance therapies (79). In pregnant women receiving a treatment dose of LMWH, 
anti-Xa monitoring is controversial and not evidence-based (141). Periodic testing of anti-
Xa levels may be indicated in women at extremes of weight (<50 kg or >90kg), women who
are bleeding or at bleeding risk, women with recurrent VTE despite treatment, and women 
with renal failure. Guidelines recommend that a treatment dose of LMWH should be 
continued throughout the pregnancy and for at least 6 weeks in the postpartum period, 
until at least 3 months has been given in total(10,67). After 3 months’ initial treatment, 
dosing intensity could be decreased to an intermediate (75% of full-treatment dose) or 
prophylactic dose for the remainder of the pregnancy for at least 6 weeks’ postpartum (79).
Women with acute VTE should be hospitalized  (especially in cases with PE or of 
hemodynamic instability) or followed closely as outpatients for at least the first 2 weeks 
(9). 
A recent placebo-controlled multicenter randomized trial of active versus placebo elastic 
compression stockings used for 2 years to prevent post-thrombotic syndrome or leg pain 
found no benefit of elastic compression stockings (142). Royal College of Obstetricians and 
Gynaecologists guidelines still (67), nevertheless, advise wearing  elastic compression 
stockings on the affected leg to reduce pain and swelling, but clinicians should be aware 
Table 5: Treatment-doses of acute VTE
Initial dose Early pregnancy weight (kg)
<50 50-69 70-89 90-109
Enoxaparin (mg bd) 40 60 80 100
Dalteparin (iu bd) 5000 6000 8000 10000
Tinzaparin 175 units/kg once daily (all weights)
>110 kg: haematologist should advise on LMWH dose
bd, twice daily
Table extracted from Royal College of Obstetricians and Gynaecologists 
Green Top guideline 2015b
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that the benefit in the prevention of PTS is unclear. Early mobilization has not been 
demonstrated to increase the risk of PE once the patient is stable and anticoagulated in 
non-pregnant patients. The same management seems to apply in pregnancy (143), page 92.
Prevention of recurrent VTE in women with prior VTE(s)
The management of pregnant women starts with accurate assessment of their risks of VTE.
Accurate and sensitive counseling of the risks of VTE, signs and symptoms of VTE, and 
benefit of thromboprophylaxis of women is required. 
Women with previous VTE should be stratified into intermediate-risk, high-risk, and very 
high-risk groups by taking into account the circumstances of previous VTE and possible 
thrombophilia status (10). Table 6 lists the VTE risk by type of thrombophilia and 
circumstances of possible prior VTE.  
Very high risk Treatment recommendation
Prior VTE on long-term warfarin Antenatal weight-adjusted treatment/
Antithrombin deficiency intermediate LMWH dose and
APS+previous VTE
High risk Treatment recommendation
Prior recurrent or unprovoked VTE Antenatal and 6 weeks’ postnatal
Prior estrogen-related VTE LMWH with prophylactic doses
Prior VTE + thrombophilia
Prior VTE+ family history of VTE
Thrombophilia(combined defects
or homozygous FVL or prothrom-)
bin gene mutation) without prior VTE
Intermediate risk Treatment recommendation
Single previous VTE associated 7 days postnatal prophylactic LMWH
with transient risk factor, 6 weeks if other risk factors present
no family history or thrombophilia
Thrombophilia without prior VTE
(other than above mentioned)
VTE, venous thromboembolic event;  LMWH, low-molecular weight heparin ;VKA, vitamin K antagonist
Table 6. Stratification and management of VTE risk by type of
thrombophilia and circumtances of possible prior VTE
6 weeks’ postnatal LMWH or VKA
APS, antiphospholipid syndrome, Low-dose aspirin is recommended for all women with APS
Extracted from Book: Cohen H, O’Brien P. Disorders of Thrombosis and Hemostasis in Pregnancy A Guide to
Management. 2nd.ed. Springer-Verlag London 2015; p. 85.
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Table 7 presents the suggested LMWH dosing regimens for prophylaxis against pregnancy-
related VTE.  The risk factors for bleeding and contraindications for LMWH should also be 
assessed (79).  Table 8 shows the risk factors for bleeding.
Table 7: Suggested LMWH-doses for prophylaxis against
pregnancy-related VTE
Prophylactic LMWH a
Dalteparin 5000 units once daily
Tinzaparin 4500 units or 75 units/kg  once daily 
Enoxaparin 40 mg once daily
Nadroparin 2850 units once daily
Intermediate-dose LMWH a
Dalteparin 5000 units twice daily or 10.000 units once daily
Tinzaparin 10.000 units once daily
Enoxaparin 40 mg twice daily or 80 mg twice daily
LMWH adjusted to a peak anti-Xa level 0,2-0,6 units/ml
aHigher doses might be used in with increased maternal weight
LMWH, low-molecular-weight heparin
Extracted from the Guidance for the treatment and prevention of obstetric-associated venous
thromboembolism (Bates et al. 2016)
Table 8: Risk factors for bleeding
Active antenatal or postpartum bleeding
Increased risk of major hemorrhage
(e.g. placenta previa)
Bleeding diathesis (von Willebrand’s 
disease, hemophilia, coagulopathy)
Thrombocytopenia (platelet count <75*109/l)
Acute stroke in the last 4 weeks (ischemic or
hemorrhagic)
Uncontrolled hypertension (systolic BP>200 mmHg
mmHg or diastolic BP >120 mmHg)
Severe liver or renal disease
BP, blood pressure
Extracted from Book: Cohen H, O’Brien P. Disorders of
Thrombosis and Hemostasis in Pregnancy
A Guide to Management. 2nd.ed. Springer-Verlag London 2015; p.
85.
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Patients with AT deficiency and a history of VTE, particularly type I, have a very high risk 
of recurrent thrombosis. Before pregnancy, these patients are likely to be on long-term 
warfarin, and therefore, weight-adjusted treatment dose or intermediate dose of LMWH 
may be indicated throughout pregnancy until 6 weeks’ postpartum, when long-term 
warfarin is again initiated. The efficacy of heparins in AT deficiency is unclear (mode of 
action is antithrombin-dependent), thus monitoring of anti-Xa levels would be reasonable 
and antithrombin substitution during delivery is often needed (144). 
Prevention of VTE in women with asymptomatic thrombophilia 
There are limited data on benefits of antenatal LMWH prophylaxis of asymptomatic 
women with a known heritable thrombophilia, other than those with antithrombin 
deficiency or combined/homozygous defects, for whom antenatal LMWH prophylaxis is 
usually necessary (79,144,145). VTE risk should be assessed individually and considered 
along with possible family history and other risk factors before reaching a conclusion. 
When other risk factors, such as age >35 years, obesity, or immobility, are present, the use 
of antenatal LMWH prophylaxis could be beneficial (79). Postpartum LMWH prophylaxis 
(10 days to six weeks) in these situations is, however, recommended by the majority of 
guidelines, especially if other risk factors exist (79). 
Prevention of VTE in women with another clinical risk factors
Recent publications have used large databases to provide population-level absolute and 
relative risks for VTE (146,147). Most established risk factors have only a modest effect on 
VTE risk, with a few increasing the absolute risk by about 1%. It is unclear how 
combinations of independent risk factors affect the overall VTE risk and whether they 
result in additive or multiplicative risks. Further research in this field is required (79). The 
clinical risk factors and the estimated risk shown as adjusted OR/HR were earlier listed in 
Table 3. Clinical risk factors for VTE antepartum and postpartum and an example of a risk 
assessment tool combining all of the clinical risk factors demonstrated to increase VTE risk
are shown in Table 9. 
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Table 9. Ante-and postpartum risk assessment and management
Antepartum LMWH-prophylaxis Postpartum LMWH-prophylaxis
Initiate from beginning of the At least 6 week 
pregnancy if following:
Any previous VTE
Prior VTE (not related to major surgery) Anyone requiring antenatal LMWH
High-risk thrombophilia
Consider if following: Low-risk thrombophilia + family
history of VTE
Prior VTE related to major sugery
High risk thrombophilia (no prior VTE) At least 10 days
Hospital admission If persisting or>3 risk factors
consider extending
Surgery during pregnancy
Cesarean section in labour
≥4 risk factors: from the first trimester
Hospitalization ≥3 days
<3 risk factors : mobilization + avoidance Surgery (except repair of the 
of dehydration if following: perineum)
Low-risk thrombophilia
At least 10 days
Parity≥3 ≥2 risk factors
Age>35 years <2 risk factors: mobilization + avoidance 
Current smoking of dehydration if following:
Gross varicose veins
Current pre-eclampsia Age>35 years
Immobility (paraplegia) BMI≥30 kg/m2
Family history of VTE Parity≥3
Multiple pregnancy Current smoking
Elective Cesarean section
Family-history of VTE
LMWH, low-molecular weight heparin; Low-risk thrombophilia
VTE, venous thromboembolic event Gross varicose veins
Prolonged delivery (>24 hours)
IBD, inflammatory bowel disease, Postpartum hemorrhage (>1 l)
IV,intravenous Preterm delivery (<37 gestational weeks)
Stillbirth in this pregnancy
Multiple pregnancy
technology
Modified table extracted from two different tables 
Royal College of Obstetricians and Gynaecologists Green-top Guideline No. 37b
Medical comorbidities (SLE, IBD, IV drug user)a
OHSSb (first trimester only)
BMI≥40 kg/m2
3 risk factors: from 28th gestational week
Medical comorbidities (SLE, IBD, IVDU)a
BMI>30 kg/m2
IVF/ARTc
aSLE, systemic lupus erythematosus, 
bovarian hyperstimulation syndrome
c in vitro fertilization/assisted reproductive
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The use of elastic compression stockings is recommended in pregnancy and in puerperium 
for women who are hospitalized and have a contraindication to LMWH.  Elastic 
compression stockings are also recommended to reduce venous stasis for women who are 
hospitalized after Cesarean section (possible combined with LMWH) and for those 
considered to be at particularly high risk of VTE (e.g. previous VTE, more than four risk 
factors antenatally, or more than two risk factors postnatally) (133). However, there are no 
trials to support the use of elastic compression stockings in pregnancy and in puerperium, 
with existing recommendations largely derived from extrapolation of results for the 
hospitalized non-pregnant population (148) 
Management before delivery 
Timing of delivery could be considered in women who receive a weight-adjusted treatment 
dose of LMWH. Guidelines recommend discontinuation of LMWH at least 24 hours before
the expected time of neuroaxial anesthesia. If spontaneous labor occurs, neuroaxial 
anesthesia should not be used due to a risk of paraparesis caused by a dorsolumbar 
epidural hematoma (149). Women with DVT within 2-4 weeks before delivery may be 
candidates for placement of a retrievable inferior vena cava filter. Guidelines recommend 
discontinuing prophylactic or intermediate-dose LMWH upon onset of spontaneous labor 
or a planned induction of labor or Cesarean section. Neuroaxial anesthesia can be 
administered 10-12 hours after the last dose of LMWH. LMWH may be started 4-6 hours 
after neuroaxial catheter removal upon occurrence of full neurologic recovery and no 
evidence of bleeding (79,149). 
Prevention of adverse obstetric outcomes in women with 
thrombophilia
Pregnancy outcome could be improved significantly in women with obstetric APS.  Today, 
low-dose aspirin combined with LMWH is recommended for women with obstetric APS 
(150). This treatment combination has been shown to lead to a live birth rate of over 70% 
(151-153). The live birth rate with low-dose aspirin alone was 42% compared with 71% for 
32
the combination of low-dose aspirin and heparin  (151). Low-dose aspirin predominantly 
inhibits cyclo-oxygenase-1 , which leads to a reduction in the synthesis of thromboxane A2 
without affecting the synthesis of prostacyklin, restoring the ratio of the two substances to 
a more normal value in women with a history of obstetric complications (154). Low-dose 
aspirin appears to promote successful embryonic implantation in the early stages of 
pregnancy by protecting the trophoblast from attack by aPL. Later in pregnancy, the 
combination treatment helps to protect against subsequent thrombosis of the 
uteroplacental vasculature (155,156). The American College of Chest Physicians guideline 
recommends prophylactic dose LMWH in combination of low-dose aspirin to prevent 
pregnancy loss (10), suggesting that prophylaxis be initiated as soon as pregnancy is 
confirmed and continuing until 6 weeks’ postpartum (157). 
The thromboprophylactic therapy to prevent obstetric adverse outcomes in hereditary 
thrombophilias has been investigated, but no benefit has been found. In a recent meta-
analysis with eight trials, LMWH in women with hereditary thrombophilia and prior late 
(≥10 gestational weeks) or recurrent early (<10 gestational weeks) pregnancy loss did not 
improve live birth rates relative to those without LMWH (RR 0.81, 95% CI 0.55-1.19, 
p=0.28) (158). 
Another meta-analysis with eight trials showed that LMWH did not significantly reduce 
the risk of recurrent placenta-mediated pregnancy complications (early or severe pre-
eclampsia, FGR, placental abruption, pregnancy loss ≥20 gestational weeks) in women 
with hereditary thrombophilia (absolute difference -2.3% (95% CI -17.6-13.0, p=0.77) for 
those with heterozygous FV Leiden or prothrombin gene mutation and -2.0% (95% CI 
-13.8-9.9, p=0.74) for those with stronger thrombophilias) (159). The EAGeR (multicenter 
randomized trial), in which one group received preconceptionally initiated low-dose 
aspirin plus folic acid and the second group received placebo plus folic acid, revealed no 
difference in live birth rates and pregnancy losses between the groups (160). 
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Anticoagulants in pregnancy
Unfractionated heparin (UFH)
Pharmacokinetics of UFH 
Heparin is a sulphated glycosaminoglycan that activates antithrombin, leading to rapid 
inhibition of the procoagulant activity of thrombin and factors IXa, Xa, XIa, and XIIa 
(161). Commercial preparations of heparin are heterogeneous. They consist of saccharide 
units with molecular weights ranging from 3000 to 30000 daltons (mean, 15000). The 
interaction with antithrombin is mediated by a unique pentasaccharide sequence. Any 
pentasaccharide-containing heparin chain can inhibit the action of factor Xa, but to 
inactivate thrombin, heparin must bind to both antithrombin and thrombin by forming a 
complex, which can be formed only by pentasaccharide-containing heparin chains 
composed of at least 18 saccharide units (162). These longer pentasaccharide sequences are
distributed randomly to only one-third of the chains of UFH, which is why only about one-
third of the heparin binds to antithrombin (163). UFH affects hemostasis also in many 
other ways, e.g. by inhibiting platelet function (164) and increasing the permeability of 
vessel walls (165). 
UFH in clinical use 
UFH is poorly absorbed from the gastrointestinal tract so it must be administered 
parenterally or subcutaneously (166). It has complex pharmacokinetics with nonlinear 
anticoagulant response and wide inter-patient variation (167). UFH does not cause fetal 
bleeding or teratogenicity because it does not cross the placenta(168). Anticoagulation with
UFH as a continuous intravenous infusion requires regular activated thromboplastin time 
monitoring (APTT) and dose changes according to results. Twice daily injections are 
required if administrated subcutaneously due to the short half-life (169). The intensity and 
duration of the anticoagulant effect rise disproportionately with increasing doses, 
predisposing women to bleeding complications (170,171). 
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The most important complication of long-term use of UFH is osteoporotic fractures (172). 
The decrease in BMD is due to decreased bone formation and increased resorption since 
UFH reduces the number and activity of osteoblasts and increases the number and activity 
of osteoclasts (173,174). The incidence of symptomatic bone fractures after long-term UFH 
use during pregnancy is reported to be 2-9% (20,21). 
Another disadvantage of UFH is the risk of heparin-induced thrombocytopenia (HIT), 
which is a life-threatening antibody-mediated effect of heparin that leads to arterial and 
venous thrombosis, typically occurring 5-10 days after the first UFH dose. The pathogenic 
IgG antibodies recognize complexes of platelet factor 4 and heparin, leading to 
intravascular platelet activation. Clinical features of HIT are thrombocytopenia (more than
50% platelet count fall rapidly but not lower than 20*109/litre) and venous and arterial 
thrombotic events (175). The risk of HIT for non-pregnant patients receiving therapeutic 
doses of UFH is estimated to be 3% (176). For pregnant women on a prophylactic dose of 
UFH, the incidence of HIT is variable: between 0.1% and 1% (177). 
Low-molecular-weight heparin (LMWH)
Pharmacokinetics of LMWH
LMWHs are fragments of UFH produced by controlled enzymatic or chemical 
depolymerization processes, the end-products of which are chains with a mean molecular 
weight of about 5000 Da. Like UFH, LMWH acts by activating antithrombin. However, 
while almost one-third of UFH chains contain the pentasaccharide sequence of at least 18 
saccharide units, only 15-25% of LMWH chains contain this sequence  (178). Relative to 
UFH, which has activity against factor Xa and thrombin, fewer LMWHs are of sufficient 
length to bind to both antithrombin and thrombin, so LMWHs have a greater activity 
against factor Xa (179). The inhibitory activity of LMWHs against factor Xa persists longer 
than their inhibitory activity against thrombin, reflecting the more rapid clearance of 
longer heparin chains (169).
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however accumulate in patients with renal failure (creatinine clearance of less than 30 
ml/min) leading to increased bleeding risk especially when therapeutic doses are 
administered (171). The most commonly used LMWHs are dalteparin, enoxaparin and 
tinzaparin. 
Vitamin K antagonists
Vitamin K antagonist inhibits vitamin K oxide reductase, which is the enzyme responsible 
for the cyclical conversion of oxidized vitamin K to its reduced form, and then participates 
in the carboxylation of the coagulation factor precursors. This, in turn, inhibits the K-
vitamin-dependent process to change the coagulation factors II, VII, IX, and X to 
procoagulants (182). Warfarin sodium is the most used VKA in clinical use outside 
pregnancy. It has many disadvantages, including slow onset of action, narrow therapeutic 
window, and necessitation of frequent monitoring (183). It crosses the placenta and can 
lead to miscarriage, stillbirth, preterm birth, embryopathy, and hemorrhagic complications
to the fetus. Manifestations of the warfarin embryopathy include nasal hypoplasia, 
epiphyseal stippling, ocular abnormalities, and hypoplasia of the extremities. The critical 
period of exposure for embryopathy appears between gestational weeks 6 and 12 (183). 
During pregnancy its use is limited to rare occasions in women with mechanical heart 
valves. It is then, however, recommended to substitute with heparin between 6 and 12 
weeks to reduce the risk of harmful effects to the fetus. However, this increases the risk of 
thromboembolic complications in those with mechanical heart valves (184).
Direct oral anticoagulants (DOACs)
Direct oral anticoagulants (DOACs) are increasingly used also in fertile-aged women for 
prevention and treatment of arterial and venous thrombotic diseases. Dabigatran is a 
direct thrombin inhibitor. Rivaroxaban, apixaban, and edoxaban are direct factor Xa 
inhibitors (185). These preparations are contraindicated during pregnancy since published 
experience with them is scarce (186). Animal studies of dabigatran and rivaroxaban have 
demonstrated fetal loss and harm (186). Dabigatran crosses the human placenta (187). 
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Case series of 37 women using rivaroxaban at the beginning of pregnancy exist. All of these
individuals discontinued rivaroxaban upon discovery of a positive pregnancy test (188). 
One major malformation (conotruncal cardiac defect) occurred in a woman with a previous
fetus with cardiac malformation (without exposure of rivaroxaban in this pregnancy). 
Although results of the case series might be reassuring, the limited cohort size does not 
rule out increased malformation risk and does not support the use of rivaroxaban during 
pregnancy (188). It is also unknown whether DOACs are excreted in breast milk (186). 
Safety and efficacy of LMWH during pregnancy
Previous studies focusing on safety and efficacy of LMWH 
Because of disadvantages of UFH, such as osteoporotic fractures, HIT, bleeding, and 
impracticality, LMWH has replaced UFH since the 1980s (19). Prospective trials regarding 
the safety and efficacy of LMWH are scarce mainly due to ethical reasons. Earlier data and 
recommendations regarding these issues in pregnancy were based on extrapolation of data 
from non-pregnant patients (137,189). Currently, several retrospective case series and one 
large prospective study also exist with pregnant patients (11-14,18). Table 10 summarizes 
the results of the largest studies with 100+ patients who received prolonged LMWH for 
various indications during pregnancy. Knowledge about the safety and efficacy of LMWH 
has increased with the wide use of this medication in pregnant women. A systematic 
review (19) of 64 different studies reporting the safety and efficacy of LMWH in 2777 
patients demonstrated LMWH to be safe and effective. VTE was reported in 0.86% and 
arterial thrombosis in 0.50% of pregnancies. Significant bleeding (>500 ml), mainly 
associated with obstetric causes, occurred in 1.98%, allergic reactions in 1.80%, 
trombocytopenia in 0.11%, and osteoporotic fractures in 0.04% of patients. No HIT or 
maternal deaths occurred. The total live birth rate was 94.7%. LMWH was found to be 
effective also for those patients with recurrent pregnancy loss; 85.4% of these pregnancies 
resulted in live birth. 
Study VTE
n n/n n(%) n(%) n (%)
624 49/574 20 (3.2) 8 (1.3) 10 (1.6) 0
111 0/111 3 (2.7) 6 (5.4) 5 (4.5) ?
810 0/810 24 (3.0) 5 (0.6) 18 (2.2) ?
1267 254/1013 10 (0.9) 15 (1.2) 35 (2.8) 6 (0.5)
166 13/153 11(7.2) 0 0 2 (1.2)
326 0/326 20 (6.2) 4 (1.2) 0 ?
130 2/128 2 (1.5) 1 (0.8)d 0 1 (0.8)
149 21/128 3 (3.6) 2 (1.3) 0
Table 10: Summary of studies investigating the maternal safety and efficacy of LMWH during pregnancy
Pregnancies Indication (T/P) LMWH-type used Major bleeding (≥1 litre) ThrombocytopeniaAllergic reactions
Lepercq et. al. 2001 Enoxaparin
Deruelle et al. 2005 4 types of LMWHa
Bauersachs et al. 2007 Dalteparin
Nelson-Piercy et al. 2011 Tinzaparin
Andersen et al. 2010 Tinzaparin/Dalteparin
Lindqvist et al. 2011 Dalteparin
Santoro et al. 2009 3 types of LMWHb
Khalifeh et al. 2014 Tinzaparin 27 (18%)c
T, treatment; P, prophylaxis
a Dalteparin, Tinzaparin, Nadroparin and Enoxaparin
b Nadroparin, Enoxaparin and Dalteparin
c >500 ml ml
d superficial VTE
(Khalifeh et al. 2014, Lepercq et al. 2001, Deruelle et al. 2007, Bauersachs et al. 2007, Andersen et al. 2010, Lindqvist et al. 2011, Nelson-Piercy et al. 2011, Santoro
et al. 2009)
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Decrease in bone mineral density
Osteoporosis is a systemic skeletal disease characterized by low bone mass, increased bone 
fragility, and risk of fractures (190). Bone mineral density is expressed either as an 
absolute value (g/cm2) or as a T- or Z-score. T-score measures the difference by number of 
standard deviations of an individual BMD from the mean of a young female reference 
population. Z-score is the number of standard deviations by which a patient s᾽ BMD differs 
from the average BMD of a population of the same age, sex, and ethnicity (190). In 
osteoporosis, the T-score is -2.5 or less and in osteopenia between -2.5 and -1 (190). 
During normal pregnancy maternal bone loss of 1-4% may occur in the last months of 
pregnancy, when the fetal skeleton is rapidly mineralizing (26). During lactation there is an
additional mobilization of calcium from maternal bone, which can lead to a transient loss 
of 5-10% in BMD, but this is restored 6-12 months after cessation of breastfeeding (47). 
UFH decreases bone formation and increases bone resorption by reducing the number and
activity of osteoblasts and increasing the number and activity of osteoclasts (173). LMWH 
might have a lesser effect on BMD by acting only on bone formation, and it has been found 
to cause 6- to 8-fold less inhibitory effect on bone nodule formation than UFH (191,192). 
Most studies (although with small sample sizes) investigating the association of long-term 
LMWH use and decrease in BMD have found no or only a minor effect on BMD (21,193-
195). Prolonged UFH use during pregnancy has been reported to be associated with 2-9% 
of symptomatic osteoporotic vertebral fractures (20,21). However, some case reports of 
LMWH-associated osteoporotic fractures exist (196). In a review of 11 cases of LMWH-
induced osteoporotic fractures, eight occurred during pregnancy (197). 
The combined data of these studies suggest that the risk for developing an osteoporotic 
fracture after prolonged use of a prophylactic dose of LMWH during pregnancy is low, 
although data on therapeutic doses and long-term BMD are limited. Previous literature 
suggest, however, that some negative effect on BMD after long-term prophylactic LMWH 
exposure during pregnancy may exist, but because of the small sample sizes in the studies 
this is only speculative. The effects of LMWH on BMD require further investigation.    
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Recurrent VTE during pregnancy despite LMWH-prophylaxis
As earlier mentioned, the most important risk factor for VTE in pregnancy is a personal 
history of VTE, with the increased recurrence risk being 3- to 4-fold (80).  However, only a 
few studies limited to women with a history of VTE concerning recurrent VTE during 
subsequent pregnancy exist. Moreover, studies evaluating recurrent VTEs despite LMWH 
prophylaxis are very scarce.  
The risk of recurrent VTE antepartum if LMWH prophylaxis is withheld is 2.4-7.4% 
according to four previous studies (82-84,198). The subjects participating in these studies 
are heterogeneous in terms of circumstances of previous VTE. The study with the lowest 
incidence, 2.4% (82), was limited to low-risk women without thrombophilia enrolled in 
mid-pregnancy (early VTEs could have been missed). The risk of recurrent VTE during the 
postpartum period without thromboprophylaxis was 6.7-8.3% according to three previous 
studies (83,84,198). 
In a prospective trial (12)with 810 pregnant women, 5 recurrent VTE events (0.6%) 
occurred in the high-risk and very high-risk groups that received weight-adjusted LMWH  
(50–100 IU and 100–150 IU/kg/day, respectively) initiated in early pregnancy until 6 
weeks’ postpartum. The authors concluded that risk-stratified LMWH prophylaxis was 
associated with a low incidence of symptomatic VTE.  
A large prospective follow-up study with 326 pregnant women on prophylactic LMWH 
initiated in early pregnancy found that the incidence of recurrent VTE was 0.6% 
antepartum and 0.6% postpartum (0-42 days). All women had a history of one prior VTE 
(antithrombin deficiency and APS excluded). The authors concluded that LMWH was 
effective (relative risk reduction 88%). The postpartum VTE risk when LMWH was 
stopped (43-100 days) was 0.9%, and it was 28-fold relative to the control group of 
delivered women without prior VTE (18). 
A retrospective cohort (17) with 44 pregnancies of intermediate risk (LMWH for 6 weeks’ 
postpartum) and 82 pregnancies of high risk (LMWH antepartum and for 6 weeks’ 
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postpartum) found that the incidence of pregnancy-related VTE was 5.5% (n=7) . All VTE 
episodes occurred in women at high risk (5 events postpartum, 2 events antepartum). All 
episodes occurred in women with a previous VTE: five were hormone-related, four had 
underlying thrombophilia. Of the postpartum events, 40% occurred after 6 weeks’ LMWH 
prophylaxis, suggesting that in the high-risk group postpartum prophylaxis for 6 weeks 
might be too short.   
Allergic skin reactions 
Cutaneous allergic reactions have been reported to be associated with the use of LMWH, 
UFH, and warfarin.  These skin reactions vary from local allergic manifestations to skin 
necrosis and can be confirmed by intracutaneous testing (199). Generally, they occur 3-10 
days after the initiation of treatment, but may also occur later. The incidence of LMWH-
associated allergic skin reactions has been found to be 0.5-1.2% (13,14,200). 
In patients with heparin-induced skin reactions, danaparoid, a “low-molecular-weight 
heparinoid” that differs in chemical structure and is free of heparin fragments, may be 
used after negative intracutaneous testing in some patients (201). Because danaparoid is 
not always available, fondaparinux (a synthetic analog of the heparin pentasaccharide 
sequence) is commonly used as alternative in patients with allergic skin reactions or HIT 
associated with LMWH. Although transplacental passage of fondaparinux can occur, no 
complications in the mother and child have been shown in case reports (202). 
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Aims of the study 
The aims of the study were to investigate
I. The maternal and fetal safety of long-term LMWH exposure during pregnancy and 
its efficacy in preventing VTE during pregnancy
II. The incidence and risk factors of recurrent antepartum VTE in women with a 
history of one or more prior VTEs
III. The possible subsequent decrease of BMD in lumbar spine and/or femoral neck 
after long-term LMWH exposure during pregnancy and/or during the postpartum 
period
IV.   To calculate the cumulative and weekly incidence of VTE and mortality through 
180 postpartum days, to identify the associated risk factors during three different 
postpartum periods, and to compare the incidence of postpartum VTE with that of 
the non-pregnant fertile-aged female population to determine when the risk of VTE 
decreases to baseline levels.
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Materials and Methods
Study design 
A description of the studies is presented in Table 11. The study design is a retrospective 
observational cohort (Studies I-III) undertaken at the Department of Obstetrics and 
Gynecology, Helsinki University Hospital, Finland. Selection bias in Studies I-III was 
avoided by checking the data of all participants from the electronic hospital database. 
Study IV is a population-based controlled cohort based on the data of five large registers in
Finland in 2001-2011 (The Care Register for Health Care (HILMO), The Medical Birth 
Register, the Cause of Death Register, Population Register Centre and The Register of 
Induced Abortions) . HILMO is one of the oldest individual-level hospital discharge 
registers covering the entire country. It has been intensively used for research purposes. 
Completeness and accuracy in the register seem to vary from satisfactory to very good. The 
accuracy of registry-based diagnoses has been shown to be good; more than 95% of 
discharges could be identified from the HILMO (203).  Moreover, multiple data sources 
and register linkages used increase the completeness of data.  
Table 11: Materials and Methods in studies I-IV
Study I Study II Study III Study IV
Study group Women with LMWH-exposure LMWH-exposed women Women with LMWH-exposure Women aged 15-49 years
for different indications during with ≥one prior VTE for different indications during with registered delivery
pregnancy and untreated controls( ubstudy of study I) pregnancy and untreated controls
Time frame February 1994-January 2007 February 1994-January 2007 2008-2012 2001-2011
Design Retrospective observational Retrospective observational Retrospective A population-based 
cohort cohort observational cohort controlled cohort
Outcome Maternal or fetal complications Recurrent VTE despite Subsequent decrease of BMD in Incidence, risk and mortality
during pregnancy and LMWH-prophylaxis or before lumbar spine/femoral neck of VTE during six months
pregnancy outcome the planned LMWH-initiation 4-7 years after the delivery postpartum-period
Number of subjects 475 (648) 25 (28) 92 (107) 1169 deliveries
(pregnancies)
Number of controls 622 (626) 245 (341) 60 633.123 deliveries
(pregnancies)
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Ethical considerations
The study protocol (Studies I-III)  was approved by the local ethics committee (Studies I 
and II: 17 March 2010, Dnro 45/13/03/03/2010, and Study III: 16 September 2009, Dnro 
351/E9/2007). The Population Register Center gave permission for address data on 13 
March 2015 (Dnro THL/1374/5.05.00/2014). No ethics statement was required for Study 
IV since the study was performed with anonymous register data and none of these 
individuals were contacted.
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postpartum VTE to calculate the cumulative and weekly incidence of VTE through 180 
postpartum days and to identify the associated risk factors during three different 
postpartum periods. The non-pregnant fertile-aged population comprised all women aged 
15-49 years without registered delivery or induced abortion in the same calendar year in 
order to compare the incidence of postpartum VTE with that in non-pregnant fertile-aged 
women.  The mortality for postpartum VTE was assessed from the Cause of Death Register.
Cases and controls 
Study I
After excluding 28 LMWH-exposed patients with 33 pregnancies that ended in 
miscarriages, 475 pregnant women with 648 LMWH-exposed pregnancies remained. Six 
hundred and twenty-two untreated controls with 626 singleton pregnancies were selected 
as controls. Patients used LMWH for different indications with varying duration of 
therapy. Pregnancy, delivery, and baseline data on the participants were retrieved from the
electronic hospital database. Data on age, gravidity, parity, BMI, obstetric history, primary 
diseases, history of VTE, trombophilias, platelet count, and alanine aminotransferase 
(ALAT) values were collected. The type, dosing and duration of the LMWH therapy as well 
as any other medications used were reported. During the study period the treatment 
protocol was as follows: prophylactic dose of enoxaparin 40 mg/day or dalteparin 5000 
IU/day, intermediate dose (50% of weight-adjusted treatment dose) of enoxaparin 1 
mg/kg/day or dalteparin 100 IU/kg/day, and weight-adjusted treatment dose of 
enoxaparin 1 mg/kg twice daily and dalteparin 100 IU/kg twice daily. 
Study II
Because the proportion of those with VTE, despite ongoing LMWH medication, was so 
high in Study I, we decided to conduct a sub-study limited to those LMWH-exposed 
women with a history of at least one previous VTE. After excluding one women with non-
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accurately diagnosed VTE in the index pregnancy, 270 women with 369 pregnancies 
remained. The following data concerning the previous VTE were collected from the 
electronic hospital database: amount and type(s) of previous VTE(s), risk factors, such as 
thrombophilia, and circumstances of previous VTE. Age, gravidity, parity, BMI in 
connection with the first prenatal care visit, type, dose, and time of initiation and duration 
of LMWH therapy were also documented. Women with a history of idiopathic, estrogen-
related, or multiple prior VTE(s) were advised to initiate LMWH prophylaxis as soon as the
pregnancy test confirmed pregnancy. Women with a history of VTE in combination with 
thrombophilia initiated LMWH prophylaxis as soon as possible during the first trimester. 
Special attention to initiate LMWH prophylaxis as soon as possible was particularly 
targeted to those women with antithrombin deficiency or combined thrombophilias. VKAs 
were replaced with LMWH immediately after a positive pregnancy test. In cases with a 
history of VTE related to some causal factor, such as immobility or operation, which was 
no longer present during pregnancy, LMWH prophylaxis was initiated at gestational weeks
34-36. 
Women were divided into three groups: women with a history of VTE with successful 
LMWH prophylaxis during the index pregnancy (Group A), women with recurrent VTE in 
the index pregnancy despite ongoing LMWH prophylaxis (Group B), and women with 
recurrent VTE in the index pregnancy before the initiation of planned LMWH prophylaxis 
(Group C). Group A was used as a control group for Groups B and C when comparing risk 
factors in connection with the recurrent VTEs. 
Study III
This observational cohort study included 92 women who had received LMWH therapy (as 
prophylaxis or treatment of VTE) during their previous pregnancy/pregnancies. Fifteen 
women had a history of two LMWH-exposed pregnancies. Sixty women with no LMWH 
exposure ever were recruited as controls. A recruitment letter with information about 
DEXA and the associated marginal radiation was sent to invitees. Our primary aim was to 
select two controls for every case matched for age and parity. We finally succeeded in 
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recruiting only 60 controls because many potential controls refused DEXA. ICD-10 codes: 
I73, I74, I80, I81, I83, D68, and M32 were used to collect potential LMWH-exposed 
subjects. The parity-matched next delivered women after the index case was selected as a 
control. 
In LMWH-exposed women, DEXA measurement was performed between the years 2008 
and 2009. Due to delayed funding, DEXA in the control women was carried out between 
2011 and 2012, causing an age difference between LMWH-exposed woman and controls at 
the time of DEXA analysis. Controls were also significantly heavier than cases. 
The prophylactic LMWH dose was enoxaparin 40 mg/day or dalteparin 5000 IU/day. The 
weight-adjusted treatment dose was enoxaparin 1 mg/kg or dalteparin 100 IU/kg twice 
daily. The intermediate dose was enoxaparin 1 mg/kg/day or dalteparin 100 IU/kg/day. 
The total LMWH dose was also calculated by taking into account all LMWH-exposed 
pregnancies. All participants filled in a questionnaire regarding lifestyle factors (smoking, 
physical exercise, dietary calcium intake, and alcohol use) and medical history (menstrual 
cycle, contraception, underlying diseases, and duration of breastfeeding, etc.). Baseline 
characteristics and data on the LMWH therapy were retrieved from the electronic hospital 
database. 
Study IV
In 2001-2011, a total of 634292 deliveries were registered. Cases comprised 1169 deliveries
with a diagnosis of postpartum VTE, and the remaining 633123 deliveries without a 
diagnosis of postpartum VTE served as controls. For baseline VTE incidence, 1232841 non-
pregnant non-puerperal fertile-aged women followed up for 13.56 million woman-years 
without registered delivery or induced abortion in the same calendar year served as the 
control group. 
The women with deliveries were divided into six different age groups: 15-19, 20-24, 25-29, 
30-34, 35-39, and 40 years or more. The cumulative incidence of total VTE, DVT, and PE 
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was calculated separately in each age group. We identified VTE-associated risk factors 
during three different postpartum periods: 0-21 days, 22-42 days, 43-180 days.
Definitions and Outcomes
Primiparity was defined as no deliveries ≥22 gestational weeks before the index pregnancy,
in accordance with the International Statistical Classification of Diseases and Related 
Health Problems of the World Health Organization. 
FGR was defined according to the criteria of the American College of Obstetricians and 
Gynecologists as estimated fetal weight below the 10th percentile for gestational age (204).
Pre-eclampsia was defined as severe requiring delivery ≤ 37 gestational weeks when these 
criteria were fulfilled: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure 
≥110 mmHg and proteinuria ≥5 g/day (205). 
HIT was suspected if platelet count halved after initiation of LMWH with simultaneously 
existing  heparin-dependent IgG antibodies. 
The criteria of the antiphospholipid antibodies carrier were lupus anticoagulants and 
anticardiolipin antibody or anti-β glycoprotein-1 antibody on two or more occasions at 
least 12 weeks apart without clinical manifestations. Antiphospholipid syndrome was 
defined as 1) a clinical entity with one or more clinical episodes of arterial or venous 
thrombosis in any tissue or organ with no alternative cause of thrombosis or fetal loss and 
2) the presence of antiphospholipid antibodies.
T-score is the difference, by number of standard deviations, of an individual’s BMD from 
the mean of a young female reference population. Osteoporosis is diagnosed when T-score 
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is -2.5 or less. Osteopenia is diagnosed (decreased bone density) when T-score is between 
-2.5 and -1.  Z-score is the number of standard deviations by which a patient´s BMD differs
from the average BMD of a population of the same age, sex, and ethnicity. 
Daily calcium intake was determined based on declared calcium-containing food 
consumption by using the Fineli® nutrient composition database. 
Calibrations of the DEXA equipment were as follows:  daily calibrations by using a 
standard calibration block, which includes 3 cavities that simulate BMD values 0.5, 1.0, 
and 1.5 g/cm
2
. The BMD of every cavity must be within 0.03 g/cm
2
 of the expected value. 
Repeatability over the long term was adjusted through weekly measurements by using a 
skeleton phantom (Accuracy Phantom, SN 21979, BMD 1.265 g/cm
2
). The day-to-day 
variation of the equipment used was 0.01 g/cm
2 
and the coefficient of variation 1.0% 
(%CV= standard deviation/percentage of average BMD) for the lumbar spine and femoral 
neck.
Study I: The principal outcome variables were adverse effects of LMWH exposure, 
including bleeding, HIT, increase in ALAT values, allergic skin reactions, and osteoporotic 
fractures. Recurrent VTEs were reported. Adverse pregnancy outcomes documented were 
FGR, pre-eclampsia, preterm delivery, and stillbirth. Delivery route, blood loss at delivery, 
birth weight, 1-min and 5-min Apgar scores, and umbilical cord pH were also documented.
 
Study II: The main outcome variable was recurrent antepartum VTE despite prophylactic 
LMWH or before the aimed initiation of LMWH, which was objectively diagnosed by CUS 
or CTPA. We also retrospectively classified all women according to the risk of recurrent 
VTE based on the ACCP guidelines (James, Committee on Practice Bulletins-Obstetrics 
2011) and compared the realized LMWH initiation times with the ones recommended in 
the ACCP guidelines.
Study III: The principal outcome variables were BMDs, T-scores, and Z-scores in the 
lumbar spine and femoral neck, which were measured by using DEXA (Lunar Prodigy 
advance Full Size, encore software version 15, GE Medical Systems-Lunar Madison, WI, 
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USA).  Secondary outcome variables were established osteoporosis, osteopenia, and 
clinically evident osteoporotic fractures. 
Study IV: Primary outcomes were to identify the cumulative and weekly incidence and 
mortality of postpartum VTE through 180 postpartum days. Secondary outcomes were to 
identify the associated risk factors for postpartum VTE during three different postpartum 
periods and to calculate the baseline incidence of VTE from the non-pregnant fertile-aged 
population and compare it with the postpartum VTE incidence.
Statistical analysis
Statistical analyses were undertaken by using Statistical Package for the Social Sciences 
Versions 17,  21, and 23 (SPSS Inc., Chicago, IL, USA) and the statistical software package 
SAS 9.3 (SAS Institute Inc., 100 SAS Campus Drive Cary, USA) . Qualitative variables were 
reported by using frequencies and percentages. Continuous variables were reported by 
using means (when data were normally distributed) and medians and ranges (when data 
deviated from normal distribution). Frequencies were compared by using Chi-squared test 
or Fisher’s exact test and means by using Student’s t-test or Mann-Whitney U-test. Only 
valid percentages were calculated. All tests were two-tailed and p-values <0.05 were 
considered to be significant. Multivariate regression analysis was used to adjust outcome 
variables for potential confounding factors. Multivariable logistic regression and 95% 
confidence intervals (CIs) were used to evaluate the factors associated with postpartum 
VTE risk. 
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Results
Safety of LMWH during pregnancy (Study I)
Table 12 summarizes the adverse events of LMWH and the maternal/neonatal adverse 
outcomes. The use of LMWH during pregnancy was safe. No osteoporotic fractures or HIT 
were found. The incidence rates of bleeding and thrombocytopenia did not differ between 
the LMWH-exposed women and the controls. The incidence of allergic skin reaction was 
low. Birth weight (3.4 kg vs. 3.5 kg, p=0.02) was lower in the LMWH group than in the 
control group, otherwise pregnancy outcomes did not differ between the groups. When the 
60 pregnancies with prior adverse pregnancy outcomes in the LMWH group were 
excluded, no difference in incidences of preterm delivery, stillbirth, severe pre-eclampsia, 
or FGR existed between the groups. The rate of recurrent VTEs despite ongoing LMWH 
was, however, high (2.5%, n=16). 
LMWH Control p-value
Adverse events of LMWH n (%) n (%)
56 (8.7) 32 (8.7) 0.8
Antenatal bleeding 69 (10.7) 49 (7.8) 0.07
Allergic skin reactions 2 (0.3) 0
Increase in ALAT U/l 53 (23.5) 16 (12.3) 0.01
Venous thrombosis despite LMWH 16 (2.5) 0
Bleeding during delivery >1000 ml 41 (6.8) 27 (4.5) 0.1
Heparin-induced thrombocytopenia 0 0
Osteoporotic fractures 0 0
51 (8.7) 41 (6.5) 0.05
Stillbirth 4 (0.7) 2 (0.3) 0.4
Severe pre-eclampsia 9 (1.4) 6 (1.0) 0.4
16 (2.7) 14 (2.2) 0.6
LMWH, low-molecular-weight heparin, ALAT alanine aminotransferase
Table 12: The incidence of obstetric adverse events in
LMWH-group and in control-group
Thrombocytopeniaa 
Adverse pregnancy outcomesb
Preterm deliveryc
Fetal growth restrictiond
aplatelet count <150 E9/l
b only those women (LMWH-group) without prior adverse pregnancy
outcome, n=588
c<37 gestational weeks
d <10th percentile
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The indications for LMWH were as follows: prior VTE (55.6%, n=370), acute VTE in 
current pregnancy (28.2%, n=183), previous adverse obstetric outcome (24.6%, n=159) , 
asymptomatic thrombophilia (17.7%, n=115), and other reasons such as mechanical heart 
valve, prior stroke, or immobilization (8,3%, n=53) . In 223 pregnancies, the women had 
more than one indication for LMWH use. Dalteparin (86.6%) and enoxaparin (15.7%) were
the preparations used. Sixty-eight women received low-dose aspirin as an associated 
treatment, and nine woman received UFH due to acute VTE before switching to LMWH.  
Thrombophilias were diagnosed in 197 women (41.5%). LMWH-exposed women differed 
from controls in terms of parity (fewer were nulliparous), higher BMI, and a history of 
more spontaneous abortions. The median time-point of initiation of LMWH was 17 
gestational weeks, and the mean duration of LMWH exposure was 22 weeks.
The proportion of Cesarean sections was 21% in the LMWH group and 19% in the control 
group, with no statistical difference (p=0.3).  One massive antenatal bleeding (3000 ml) 
occurred at 28 gestational weeks due to marginal placenta previa in a woman receiving 
intravenous UFH. One massive postpartum hemorrhage occurred (11000 ml) due to 
uterine atony and placental retention. Nine bleeding events were potentially LMWH-
related requiring a dose reduction or a few days’ pause in LMWH treatment.
Incidence and risk of recurrent VTE during pregnancy '
(Study II)
The proportion of successful LMWH prophylaxis was 92.4% in 341 women (Group A). 
There were 16 recurrent VTEs in 15 women despite ongoing LMWH prophylaxis (Group B) 
and 12 recurrent VTEs in 10 women before the intended start of LMWH prophylaxis 
(Group C). The overall incidence of recurrent antepartum VTE was 7.6% when analysis was
limited to those with a history of VTE.
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All VTEs in Group B were DVTs in the lower limb, mainly left-sided (56%). The mean 
initiation of LMWH prophylaxis in Group B occurred on the 7th gestational week, and the 
mean duration of LMWH prophylaxis before the recurrent VTEs was 15 weeks. In Group C,
9 DVTs occurred in a lower limb, mainly left-sided (67%), others were one PE and two 
cases of subclavian vein thrombosis. The mean time-point of diagnosis was at 10 
gestational weeks. 
Table 13 shows the medical history and risk factors for VTE in Groups A, B, and C. 
In Group B, almost half (47%) of the women had long-term VKA before the pregnancy, 
which was replaced with LMWH immediately after a positive pregnancy test. All of these 
women were at very high risk of thrombosis (two or multiple prior VTEs, VTE in 
combination with a high-risk thrombophilia and/or aPLs). Because of the high-risk profile 
in Group B, 25% of women received intermediate doses and 6% weight-adjusted doses of 
LMWH. All women in Group C received weight-adjusted treatment doses of LMWH due to 
acute VTE. 
Demographics Group A Group B Group C
n(%) 341 (92.4) 16 (4.3) 12 (3.3)
Previous VTEs n(%) <0.001 0.02
1 231 (94.3) 9 (60.0) 7 (70.0)
≥2 14 (5.7) 6 (40.0) 3 (30.0)
Long-term vitamin K antagonist 18 (7.3) 7 (46.7) 0 <0.001
Thrombophilia 64 (27.2) 8 (53.3) 4 (40.0) 0.04 0.47
34 (14.5) 2 (13.3) 2 (20.0) 1 0.64
3 (1.3) 0 1
Antithrombin deficiency 4 (1.7) 1 (6.7) 0.27
Protein C or S deficiency 9 (3.8) 1 (6.7) 1 (10.0) 0.47 0.35
6 (2.6) 3 (20.0) 0 0.012
Risk factors at first VTE
None or unknown 62 (25.3) 0 0 <0.001
Transient risk factor 64 (26.1) 6 (40.0) 2 (20.0) 0.24 1
Hormonal risk factor 148 (60.4) 14 (93.3) 9 (90.0) 0.01 0.09
Table 13: The medical history and risk factors for VTE: comparison of Groups
A, B and C
p-valuea p-value b
FV Leiden gene mutationc
Prothrombin gene mutationc
APLsd
a Group A. vs. Group B.
b Group A. vs. Group C. 
c heterozygous, dAPL, antiphospholipid antibodies
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Long-term LMWH-exposure and subsequent bone mineral 
density (Study III)
Table 14 demonstrates BMD (lumbar spine and femoral neck) in women who received 
LMWH and in controls.  BMD in the spine was significantly lower in women receiving 
LMWH than in control women, but BMD in the femoral neck did not differ between the 
groups.  No difference was found between enoxaparin users and dalteparin users in the 
lumbar spine (p=0.28) or in the femoral neck (p=0.65). 
The incidence of osteopenia was 13% in the LMWH group and 8.3% in the control group 
(p=0.40). No osteoporosis or osteoporotic fractures were found. 
Although the absolute BMD value in the spine differed between LMWH users and the 
control group, after adjustment for potential confounding factors LMWH exposure was no 
longer associated with decreased BMD in the spine. Duration of contraception pill use was 
independently associated with greater BMD in the spine. Treatment doses in the LMWH 
group were as follows: prophylactic (81.5%), weight-adjusted (10.9%), and intermediate 
(7.6%). Mean duration of prophylactic doses of LMWH was 216 days, and that of other 
doses was 218 days. Enoxaparin was used in 58% of cases and dalteparin in 42% of cases. 
The duration of contraceptive pill use was longer in the control group than in the LMWH 
group. Otherwise, the groups did not differ in terms of lifestyle factors or medical history.  
Table 14. BMD, T-and Z-scores in LMWH-group vs. control
LMWH-group Control group
Prophylactic dose
n=75 n=17 n=60
Lumbar spine
1.22 (0.09) 1.20 (0.14) 1.27 (0.14) 0.03 0.07
T-score 0.43 (0.79) 0.22 (1.19) 0.83 (1.15) 0.02 0.06
Z-score 0.44 (0.80) 0.23 (1.18) 0.93 (1.16) 0.007 0.03
Femoral neck
0.99 (0.11) 1.0 (0.15) 1.01 (0.12) 0.39 1.0
T-score 0.09 (0.91) 0.18 (1.18) 0.24 (0.97) 0.39 0.85
Z-score 0.2 (0.91) 0.28 (1.20) 0.43 (0.96) 0.15 0.58
BMD, bone mineral density; SD, standard deviation
p-valueb p-valuec
Other dosesa
BMD g/cm2 (SD)
BMD g/cm2 (SD)
a weight-adjusted - or intermediate LMWH-dose
b Women, who received prophylactic LMWH-dose vs. controls
c Women, who received weight-adjusted - or intermediate LMWH-dose vs. controls
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Incidence and risk factors of VTE during the postpartum-
period (Study IV)
Between 2001 and 2011, postpartum VTE was diagnosed in 1169 women after 634292 
deliveries between 0-180 postpartum days.  Figure 6 shows the proportion of women with 
postpartum VTE. 
The majority of the VTEs were DVTs (77%), and the rest were PEs or both (DVT+PE) 
(23%). The 180 days of cumulative incidence of postpartum VTEs was 4-fold that of non-
pregnant non-puerperal women. The incidence was highest during the first postpartum 
week: 37-fold that of non-pregnant non-puerperal women, thereafter declining to 2-fold. 
Almost half (48%) of the observed VTEs occurred between 43 and 180 days postpartum. 
Three VTE-related deaths occurred; all were PEs. Besides older age, there are many risk 
factors associated with increased risk for postpartum VTE; these are presented in Table 15.
Figure 6
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Diagnosis codes for thrombophilia were registered in HILMO in 54 (4.6%) women with 
postpartum VTE and  in 1363 (0.2%) women without it. 
Duration of the increased VTE rates varied depending on the type of risk factor. The risk 
remained elevated for 180 days in women with thrombophilia, Cesarean section, multiple 
pregnancy, varicose veins, and cardiac disease. In women with IVF pregnancy and OHSS, 
BMI≥30 kg/m2, or chorionamnionitis, the risk of VTE was increased up to 42 days 
postpartum. In women with threatening premature birth, renal disease, anemia, and 
BMI≥25 kg/m2, the risk of VTE was elevated only in the first 21 days postpartum. The VTE
risk was elevated for the first 0-6 days after childbirth for those with pre-eclampsia with  
OR 1.73 (95% CI 1.02-2.96). 
n 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
n/10000 n/10000 n/10000 n/10000
9546 47.1 23.0 5.2 18.9
265562 17.9 7.5 1.12 (0.93-1.35) 1.5 1.27 (0.83-1.94) 8.8
132219 22.6 1.10 (0.96-1.25) 10.1 1.10 (0.90-1.35) 1.7 0.93 (0.57-1.50) 10.9 1.12 (0.92-1.36)
94788 17.4 1.14 (0.97-1.35) 7.4 1.09 (0.84-1.40) 1.9 1.56 (0.92-2.63) 8.1 1.13 (0.88-1.45)
104249 26.2 11.2 2.9 12.1
13326 30.8 1.32 (0.96-1.81) 12.0 1.18 (0.71-1.94) 2.3 1.18 (0.37-3.75) 16.5 1.47 (0.95-2.26)
7186 29.2 1.51 (0.98-2.33) 6.8 1.51 (0.78-2.93) 1.5 1.18 (0.37-3.75) 7.5 1.48 (0.79-2.78)
19089 21.5 1.09 (0.79-1.49) 27.8 1.22 (0.78-1.93) 7.0 22.3 0.88 (0.54-1.45)
16523 27.2 13.3 2.4 11.5 1.30 (0.82-2.06)
1417 381.1 247.0 21.7 116
1942 56.6 30.9 10.3 25.9 2.37 (0.98-5.74)
2635 38.0 15.2 1.50 (0.56-4.04) 0.0 NA 30.4
442 67.9 1.94 (0.61-6.20) 45.2 2.50 (0.60-10.41) 0.0 NA 22.7 1.54 (0.21-11.14)
25938 13.5 0.96 (0.71-1.29) 6.9 0.86 (0.54-1.38) 2.3 1.56 (0.68-3.56) 8.1 0.95 (0.61-4.46)
1398 136.9 5.5 0.0 NA 57.6
1122 8.6 0.47 (0.07-3.32) 0 NA 0.0 NA 8.9 0.98 (0.14-6.95)
3050 136.9 1.39 (0.69-2.79) 19.7 0.0 NA 6.6 0.75 (0.19-3.00)
416 102.7 144.2 0.0 NA 146.3
145232 26,4 13.1 1.9 1.44 (0.89-2.33) 11.4
50372 31.8 18.3 2.8 10.7 1.30 (0.98-1.74)
46190 30.5 14.9 1.16 (0.87-1.55) 1.1 0.48 (0.18-1.25) 14.5
20344 11.3 1.34 (0.89-2.03) 6.9 1.0 1.46 (0.36-5.97) 3.4 0.92 (0.43-1.94)
10451 30.6 15.3 1.9 1.33 (0.32-5.43) 13.4 1.69 (0.99-2.88)
2051 14.6 0.74 (0.24-2.31) 4.9 0.52 (0.07-3.73) 0.0 NA 9.8 1.11 (0.28-4.45)
2061 58.2 29.1 9.7 19.5 2.34 (0.87-6.27)
12987 22.3 1.16 (0.80-1.68) 13.9 1.53 (0.95-2.46) 0.8 7.7 0.48 (0.07-3.49)
Table 15: Incidence of VTE 0-180 days postpartum among women with selected risk factors and adjusted OR
The Care register for Social Welfare and Health Care (HILMO)/the Medical Birth register,  deliveries n=634.292
Risk factor 0-180 days postpartum 0-21 days postpartum 22-42 days postpartum 43-180 days postpartum
Incidence Incidence Incidence Incidence
Multiple pregnancya 2.53 (1.87-3.41) 2.87 (1.88-4.40) 3.35 (1.36-8.24) 2.09 (1.30-3.34)
Primiparitya 1.24 (1.10-1.41) 1.36 (1.14-1.63)
Prior miscarriagea
Smoking during pregnancya
Cesarean sectionb 1.36 (1.19-1.57) 1.30 (1.05-1.60) 1.95 (1.25-3.02) 1.33 (1.09-1.63)
IVF-pregnancyb
Antepartum hemorrhageb
Gestational hypertensionb 1.64 (0.40-6.70)
Threatening premature birthb 1.47 (1.08-1.98) 1.65 (1.07-2.54) 1.54 (0.62-3.80)
Thrombophiliaa 20.9 (15.7-27.9) 30.8 (21.7-43.8) 14.1 (4.4-44.9) 13.1 (7.9-21.7)
IVF + Ovarian hyperstimulationa 2.94 (1.69-5.11) 3.03 (1.35-6.83) 5.59 (1.37-22.87)
Chronic hypertensiona 1.98 (1.11-3.52) 2.78 (1.38-5.61)
Systemic lupus erythematosusa
Prolonged deliveryb
Varicose veinsa 4.74 (2.87-7.82) 5.48 (2.70-11.12) 4.84 (2.39-9.79)
Hyperemesisb
Renal diseasea 2.30 (1.03-5.16)
Cardiac diseasea 12.65 (6.97-22.96) 12.95 (5.58-30.04) 14.01 (6.16-31.83)
Medical Birth Register, deliveries n= 468.671 (2004-2011)
BMI ≥25a 1.67 (1.46-1.91) 1.78 (1.46-2.15) 1.60 (1.30-1.96)
BMI≥30a 1.78 (1.50-2.12) 2.24 (1.78-2.83) 2.02 (1.12-3.63)
Gestational diabetesb 1.24 (1.01-1.5) 1.51 (1.13-2.03)
Pre-eclampsiad 1.71(1.00-2.92)
Anemiaa 1.69 (1.18-2.41) 1.75 (1.06-2.89)
Polyhydramniona
Chorionamnionitisc 3.12 (1.76-5.53) 3.25 (1.45-7.30) 6.46 (1.58-26.47)
Postpartum hemorrhagec 0.48 (0.07-3.49)
VTE, venous thromboembolic event; OR, odds ratio, CI, confidence interval; BMI, body mass index; IVF, in vitro fertilization DVT, deep venous thrombosis; PE, pulmonary embolism
NA, not available
a adjusted for age and the year of the delivery
b adjusted for age, year of the delivery and number of fetuses
c  adjusted for age, thrombophilia, year of the delivery and the number of fetuses
d OR 0-6 days postpartum 1.73 (95% CI 1.02-2.96)
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Discussion
Well-planned and conducted observational cohort studies are needed to gather 
information on the association between different risk factors and diseases. In Finland, 
where the population is small, researchers can use unique nationwide registers, such as 
HILMO, whose completeness and accuracy seem to vary from satisfactory to very good 
(203). These registers are carefully maintained according to the precise instructions 
provided by medical authorities. 
Long-term LMWH-use during pregnancy: safety and 
efficacy 
Maternal and neonatal adverse events
In study I, LMWH was found to be safe for both the mother and fetus. No osteoporotic 
bone fractures or HIT were found. The incidences of thrombocytopenia (8.7%), allergic 
skin reactions (0.3%), and antenatal bleeding (10.7%) in the LMWH group were similar to 
those in controls and in agreement with the previously published literature (19). Only one 
antenatal bleeding event was several - not related to LMWH. 
During delivery the incidences of major blood loss (>1000 ml) did not differ between 
LMWH-exposed women and controls. The rate of major blood loss during deliverywas the 
same as that in a previously published Swedish study (6.8%) (18). However, there was a 
difference between our practices and theirs in LMWH use during delivery; we 
recommended temporary cessation of LMWH prior to delivery, whereas Lindqvist et al. 
continued with a half-dose of LMWH twice daily. 
Although adverse events of LMWH were scarce, 16 women (2.5%) suffered a VTE despite 
ongoing LMWH medication.  Every woman with recurrent VTE had received LMWH for at 
least one week before the diagnosis. This finding could arise from insufficient dosing of 
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LMWH for high-risk patients due to a lack of consistent recommendations for these 
patients.
In terms of neonates, birth weight was slightly lower in the group of LMWH-exposed 
women than in controls. The explanation for this could be the higher incidence of prior 
adverse pregnancy outcomes in the LMWH group. However, this finding may be clinically 
insignificant. 
Strengths of this study were the larger sample size and the existence of controls relative to 
the majority of previously published studies with smaller sample sizes and no controls. All 
women were treated in the same hospital by a few specialists in accordance with the same 
guidelines. The available data were documented accurately in patients’ electronic hospital 
records, and the medical data were checked for each patient separately to avoid selection 
bias. 
Limitations of the study were imprecise data for some laboratory values (e.g. platelet 
count, ALAT) and bleeding events other than vaginal (e.g. epistaxis) in the control group. 
The controls were not screened for thrombophilias. Considering the size of the hospital 
and the duration of the study, the sample size was relatively small, probably due to the 
conservative approach in the 1990s during pregnancy, when indications for LMWH were 
current VTE or thromboprophylaxis for those with a history of VTE. 
In conclusion, the use of LMWH in pregnant women is safe when anticoagulation is 
needed. The high recurrent VTE rate in our study may reflect insufficient dosing of LMWH
in high-risk women.  However, at present, reports on recurrent VTEs despite LMWH 
prophylaxis are scarce, and more studies investigating the risk factors and LMWH dosing 
in connection with high-risk situations are warranted.  
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Recurrent VTEs
In study II, the incidence of antepartum recurrent VTEs was 7.6% of those with a history of
VTE. The risk factors for recurrent VTE despite ongoing LMWH were a history of multiple 
VTEs, use of long-term anticoagulation before pregnancy, a history of VTE in connection 
with antiphospholipid antibodies, and a history of VTE related to hormonal risk factor or 
of unknown etiology. The risk factors for recurrent VTE before initiation of LMWH were a 
history of multiple VTEs and a history of VTE related to prior pregnancy. 
The incidence found here was significantly higher than that of previously published 
literature focusing on efficacy of LMWH during pregnancy (0.6-2.4%)(12,17,82). 
Comparison of these studies with our study is, however, challenging because risk profiles 
of these other populations were heterogeneous and not all limited to those with a history of
VTE and anticoagulation treatment strategies were variable. The most comparable study to
our work was undertaken by Roeters van Lennep et al. (2011), who reported an incidence 
of antepartum VTE of 1.6%.  All of their VTEs occurred in high-risk women. These findings
are in agreement with our results.  
A possible explanation for the high incidence of recurrent VTEs in our hospital might be 
overly conservative dosing of LMWH in the 1990s and early 2000s due to lack of 
experience and inconsistent recommendations for LMWH treatment, particularly in high-
risk groups.
The main strength of our study is the homogeneous population; all women had a history of
VTE and were treated in the same hospital with unchanging guidelines. As far as we know, 
no previously published studies with this kind of design exist, i.e. women with treatment 
failure were compared with women with successful treatment.
A limitation of our study was its retrospective design. Data concerning confounding 
factors, such as smoking during pregnancy, were missing, which may bias the analysis. 
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Data on postpartum VTEs were not available. Data on the risk factors at the time of the 
first VTE in the control group were underreported. We did not find differences between the
groups regarding such variables as BMI>30 kg/m2 or age >35 years, probably because our 
study was underpowered for weaker risk factors. Due to the small number of women in 
Groups B and C, we were cautious in interpreting our results, merely considered them 
preliminary. 
Based on these findings, we recommend individual risk assessment and even weight-
adjusted treatment doses of LMWH in cases of high recurrence risk. LMWH should be 
initiated immediately after pregnancy is confirmed. More studies comparing different 
dosing regimens in high-risk groups are urgently needed. 
Subsequent bone mineral density
In study III, long-term prophylactic LMWH use during pregnancy was not associated with 
a subsequent decrease of BMD in the lumbar spine after adjustment for potential 
confounders. The incidence of osteopenia was similar between the LMWH group and the 
control group. No osteoporosis or osteoporotic fractures were found in either group. a 
greater LMWH dose did not correlate with decreased BMD. 
A recognized complication of prolonged UFH therapy is osteoporosis. In the 1990s, several
case series and animal studies had suggested that the decrease in BMD with LMWH is less 
than that seen with UFH (22-24). It is under investigation if LMWH associates with the 
decreased BMD. Some marginal BMD decrease was reported in a small prospective cohort 
study (n=69) with LMWH-exposed pregnancies; the authors concluded that the effects of 
LMWH on bone demineralization require further investigation (206). In studies 
comparing BMD in LMWH-exposed pregnant women with that of healthy controls, no 
association between prolonged LMWH use and decreased BMD existed (194,207). Our 
findings are in line with these studies. There are, however, eight case reports of LMWH-
induced osteoporotic fractures during pregnancy (197).  
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We found a slight positive association between combined oral contraceptive use and 
subsequent BMD. Because combined oral contraceptive use is contraindicated after VTE, 
the duration of the use of that was significantly shorter in the LMWH group than in the 
control group. Estrogens have been found to be important in the regulation of bone 
metabolism by suppressing osteoclastogenesis and inhibiting bone resorption by 
osteoclasts (208). In a review of 13 studies, nine studies indicated a favorable effect of COC
use on BMD (209). 
A strength of this study is the long follow-up time. No previous studies on BMD so many 
years after the LMWH exposure exist. Our sample size is larger than that of previously 
published studies on this same issue (21,172,193,194,207). The population was 
homogeneous; all women were Caucasians and the DEXA was carried out by the same 
equipment in the same hospital. 
Some limitations of our study must be acknowledged. Many potential parity-matched 
controls declined the DEXA, and thus, our control group remained smaller than the 
LMWH group. Baseline BMD before the LMWH exposure was not available, so 
comparison of possible BMD alterations in the same subject was not possible. Because the 
control group was recruited later than the cases, differences in age, BMI, and timing of 
DEXA existed between the groups. Information on some potential confounders, such as 
vitamin D intake, calcium supplement, sun exposure, and family history of osteoporosis, 
was missing from the questionnaire. In addition, we were unable to determine whether 
higher doses of LMWH would cause more reduction in BMD because most women 
received prophylactic doses of LMWH. The population was homogeneous; all women were 
Caucasians and the DEXA was carried out by the same equipment in the same hospital. 
Some limitations of our study must be acknowledged. Many potential parity-matched 
controls declined the DEXA, and thus, our control group remained smaller than the 
LMWH group. Baseline BMD before the LMWH exposure was not available, so 
comparison of possible BMD alterations in the same subject was not possible. Because the 
control group was recruited later than the cases, differences in age, BMI, and timing of 
DEXA existed between the groups. Information on some potential confounders, such as 
vitamin D intake, calcium supplement, sun exposure, and family history of osteoporosis, 
was missing from the questionnaire. In addition, we were unable to determine whether 
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higher doses of LMWH would cause more reduction in BMD because most women 
received prophylactic doses of LMWH.
Although these findings are promising, we conclude that indications for long-term LMWH 
during pregnancy should be based on guidelines, and lumbar spine DEXA could be 
considered after a LMWH-exposed pregnancy if other risk factors for osteoporosis exist. 
Prospective controlled studies with greater sample sizes comparing different LMWH 
dosages are required. 
Incidence and risk factors of VTE during the 
postpartum-period
In study IV, the cumulative incidence of postpartum VTE during the six months after 
delivery was 18.4/10 000 deliveries. This is higher than in the majority of other studies 
reporting incidence rates of 4-10/10000 deliveries (5,7,46,210). The incidence was highest 
during the first week after delivery: 37-fold that of non-pregnant non-puerperal women. 
The incidence of postpartum VTE declined rapidly to 2-fold, but remained at that level for 
175 days after delivery. This finding is in line with the study by Kamel et al. (2014) (28) 
who found that VTE incidence was 2-fold for 42-84 days after delivery.
Almost half (48%) of the postpartum VTEs occurred after the sixth postpartum week. This 
finding is in agreement with a previous study by Roeters van Lennep et al. (2011) (17) in 
which 40% of VTEs occurred later than six weeks after delivery in women at high risk of 
VTE, suggesting that postpartum prophylaxis for six weeks might be too short in the high-
risk groups. However, comparison of these two studies is difficult because Roeters van 
Lennep et al. evaluated a selected group of women at high risk of VTE and we had a mixed 
population of all delivered women.  
The risk of postpartum VTE increased with older age and higher BMI. Most of our findings
concerning risk factors associated with postpartum VTE are similar to those published by 
others (7,46,135). Risk factors were thrombophilia, multiple pregnancy, gestational 
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diabetes, anemia, chorionamnionitis, threatening premature birth, IVF pregnancy with 
OHSS, primiparity, CS and pre-eclampsia.  Postpartum haemorrhage was not associated 
with the risk of VTE, contrary to other studies (46,48,211). One explanation for this might 
be anticoagulation used by the women with postpartum hemorrhage. It should, however, 
be recognized that anemia, which is associated with postpartum VTE risk, might be due to 
postpartum hemorrhage. 
Women who had thrombophilia, CS, multiple pregnancy, varicose veins, or cardiac disease 
had an elevated risk of VTE up to 180 days postpartum. The VTE risk was elevated up to 42
days for women with IVF pregnancy with OHSS, BMI≥30 kg/m2, or chorionamnionitis. 
For women with threatening premature birth, renal disease, anemia, and BMI≥25 kg/m2, 
the risk of VTE was elevated only in the first 21 days postpartum. The VTE risk was 
elevated for the first 0-6 days after childbirth for those with pre-eclampsia. Our findings 
are consistent with the results of Sultan et al. (211), who found the risk of VTE to remain 
elevated for six weeks in women with pre-eclampsia, BMI>30 kg/m2, infection, and CS. 
A strength of our study was the combined data of mandatory registers with almost 635000 
deliveries. The completeness and validity of diagnosis coding of the National Medical Birth
Register and HILMO have been shown to be good (203,212).The data includes the total 
population, which improves the reliability of the analysis. Only a few studies reporting 
postpartum VTE incidence with such a long follow-up exist (27,28). Studies comparing the 
incidences of VTE in puerperal women with those in women of reproductive age outside of 
pregnancy or puerperium are also scarce (3,27,28,213). 
Some limitations must be noted. Data regarding whether VTEs are diagnosed accurately by
imaging and whether there is a history of prior VTEs were not available due to the register-
based design of this study. Moreover, restrictions prohibit Finnish health registers from 
gathering information on ethnicity. Data on patients treated in primary care were not 
available because data were retrieved only from specialized healthcare, and thus, the VTE 
incidence may have been underestimated. High-risk women with thrombophilia or other 
previously mentioned risk factors might have been anticoagulated, biasing the analysis. 
The proportion of thrombophilia in our study population was low (0.2%), even though the 
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prevalence of FV Leiden in Finland has been found to be 2-3% (92). 
Only 4.6% of women with postpartum VTE had a thrombophilia diagnosis in HILMO, 
which is significantly less than in previous studies reporting a prevalence of inherited 
thrombophilia in 20-50% of women with VTEs during pregnancy or during the postpartum
period (81).  Data concerning thrombophilias are likely to be available only for those who 
have been tested due to previous VTE or VTE in their families. It is also possible that 
diagnosed thrombophilia (D68.8) three months after the delivery is forgotten to be entered
into the electronic hospital records by the doctor, who usually discloses the diagnosis by 
phone.  
Based on these findings, we conclude that the women with these observed risk factors 
require careful consideration in terms of VTE risk during the immediate postpartum 
period. Further studies on the optimal LMWH dose and duration of LMWH prophylaxis in 
association with the above-mentioned risk factors are needed.
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Conclusions
I. The use of LMWH is safe during pregnancy when anticoagulation is needed. The 
incidences of thrombocytopenia, bleeding, pre-eclampsia, preterm delivery, 
stillbirth, or FGR did not differ between the LMWH group and the control group. 
The incidence of allergic skin reactions related to LMWH was low. No HIT or 
osteoporotic fractures occurred. The incidence of recurrent VTEs was 2.5%, which is
higher than reported by others, and thus, warrants further investigations. 
II. The risk of antepartum recurrent VTE is high in women with a history of two or 
more previous VTEs, VTE in connection with antiphospholipid antibody syndrome, 
or long-term anticoagulation. Antepartum LMWH prophylaxis with a prophylactic 
or even an intermediate dose might be insufficient in these high-risk women. For 
these women, individual risk assessment and weight-adjusted treatment dose of 
LMWH should be considered.
III.Although BMD in the lumbar spine was observed to be lower in the LMWH group 
than in the control group, no significant association between long-term use of 
LMWH during pregnancy and decreased BMD, osteopenia, osteoporosis, or 
osteoporotic fractures was found. Indications for long-term LMWH during 
pregnancy should be based on current guidelines. Lumbar spine BMD measurement
with DEXA could be considered after a pregnancy with LMWH exposure if there are
other risk factors for osteoporosis. 
IV. The risk of postpartum VTE is highest during the first week after delivery, thereafter
declining rapidly. A two-fold residual risk compared with non-pregnant non-
puerperal fertile-aged women remains through 175 days. Thrombophilia, older age, 
and higher BMI besides other significant risk factors such as CS, multiple 
pregnancy, gestational diabetes, anemia, chorionamnionitis, threatening premature 
birth and IVF pregnancy with OHSS increased the risk of VTE. Careful 
consideration of VTE risk during the immediate postpartum period is required. 
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Optimal dosing and duration of LMWH prophylaxis in high-risk women are under 
debate and further studies are warranted.
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